C. Vitae Jordi Monés 1

CURRICULUM VITAE,

July, 2018

Jordi M. Monés

PERSONAL DATA.

1. EDUCATION / QUALIFICATIONS

2. PRESENT PROFESSIONAL POSITIONS

3. PAST POSITIONS

4. INTERNATIONAL AWARDS

5. ADVISORY BOARDS and RESEARCH COMMITTEES

6. COLLABORATIVE EUROPEAN RESEARCH PROJECTS

7. BASIC RESEARCH PROJECTS

8. CLINICAL TRIALS

9. SCIENTIFIC PUBLICATIONS

10. SCIENTIFIC PRESENTATIONS

11. GRANTS

12. TEACHING ACTIVITIES and INVITED LECTURES

13. COLLABORATION IN JOURNALS EDITION and REVIEWER

14. THESIS

15. SCIENTIFIC SOCIETIES MEMBERSHIP

16. LANGUAGES

C. Vitae Jordi Monés 2

PERSONAL DATA:

Name: Jordi Manel Monés i Carilla (Jordi M. Monés)

Address: Institut de la Màcula

Centro Médico Teknon

Àrea Vilana. Building 90

Vilana 12, 08022 Barcelona SPAIN

Telephone +34 93 5950155

Fax +34 93 5950345

E- mail: [email protected]

Web: www.institutmacula.com

Date of Birth: Barcelona, June 25, 1961.

1. EDUCATION / QUALIFICATIONS:

1.1. 09/1979 - 06/1985: LICENCIATE IN MEDICINE AND SURGERY. Qualification: Excellent. University of Barcelona. Barcelona, SPAIN.

1.2. 01/1986: SPANISH NATIONAL BOARD EXAMINATION for a Residency Position M.I.R.1985/6: National classification number: 84.

1.3. 1/86 - 12/1989: RESIDENCY IN OPHTHALMOLOGY, (Opthalmologist M.I.R.) Barraquer Institute, Barcelona, SPAIN.

1.4. 1/1990 - 06/1991: RESEARCH FELLOWSHIP IN OPHTHALMOLOGY (RETINA SERVICE). The Massachusetts Eye and Ear Infirmary, Harvard University. Boston, U.S.A.

C. Vitae Jordi Monés 3

1.5. 07/1991 - 07/1992: SURGICAL VITREORETINAL FELLOWSHIP. CLINICAL AND SURGICAL RETINA FELLOWSHIP. Retina Department, Hospital San José. Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM). Monterrey, MEXICO.

1.6. 06/2010 - 06/2012: DOCTORAL THESIS, Ph.D. Degree. DOCTOR IN MEDICINE AND SURGERY, Qualification: Cum Laude. University of Barcelona, SPAIN.

2. PRESENT PROFESSIONAL POSITIONS:

2.1. CURRENT:

2.1.1. M.D., Ph.D., Opthalmologist, Macula and Vitreorretinal Specialist and Researcher.

2.1.1.1. Founder and Director of the Institut de la Màcula Centro Médico Teknon, Àrea Vilana, Building 90, Vilana 12, 08022 Barcelona, since 2007.

2.1.1.2. Director, principal investigator and one of the founders of the Barcelona Macula Foundation: Research for Vision, since 2011.

2.1.1.3. Elected Coordinator of the Specialty of Ophthalmology at the Centro Médico Teknon, since 2010

2.1.1.4. Institut de la Màcula i de la Retina Acredited site of the network of excellence in research, European Vision Institute www.europeanvisioninstitute.org/

2.1.1.5. Member of the Steering Committee at the International Multicenter Clinical Trials Proxima A and Proxima B on Geographic Atrophy. Roche, Basel, Switzerland

2.1.1.6. Member of the Steering Committee at the International Multicenter Clinical Trials Brighter and Crystal. Novartis.

C. Vitae Jordi Monés 4

2.1.2. Scientific Advisory Boards

2.1.2.1. Member of the Scientific Advisory Board of AMD international Alliance

2.1.2.2. Member of the Region Europe Ophthalmics Network (REONET) advisory board, Novartis

2.1.2.3. Member of the European Advisory Board on Retinal Vein Occlusion, ERAB, Allergan Inc

2.1.2.4. Scientific Advisor of Opththech Inc, New York USA

2.1.2.5. Scientific Advisor of Notalvision Inc, Tel Aviv, Israel

2.1.2.6. Member of the International Advisory Board for Eylea® (VEGF- Trap eye) Bayer Schering Pharma

2.1.2.7. Clinical Advisor of CellCure NeuroSciences Ltd.

2.1.3. Other positions:

2.1.3.1. Member of the Board of Directors of Futbol Club Barcelona and Responsible of the Medical Department and Performance from 2003- 2005, and 2010-2015.

2.1.3.2. Member of the Board of Directors, Comissioner FC Barcelona Universitas and Responsible for the Sport Sciences Department, 2015-2017.

2.1.3.3. Member of the National Council of Centre for Integration of Medicine and Innovative Technologies in Catalonia (CIMTI). November, 2017

3. PAST POSITIONS:

Consultant as Vitreoretinal Specialist Ophthalmologist in:

3.1. Institut de Microcirurgía Ocular de Barcelona. (April 1993 -December 2006)

C. Vitae Jordi Monés 5

3.2. Hospital de la Creu Roja de Barcelona (1995 - Nov 2004), Consultant Ophthalmology Service. Vitreoretinal Surgery.

3.3. Associate Profesor Universitat Autònoma de Barcelona in: (2003 - 2006) Cátedra (Professorship) Institut de Microcirurgia Ocular de Barcelona Universitat Autónoma de Barcelona

3.4. Member of the Board of Directors (Junta Directiva) of FUTBOL CLUB BARCELONA. Responsible of the Medical and Sport Medicine Department of Futbol Club Barcelona. June 03 - June 05

3.5. Elected Coordinator of the Specialty of Ophthalmology at the Centro Médico Teknon. Feb 10 - Feb 12

Main Fields of professional interests:

His research particular fields of interest are macular diseases, choroidal neovascularization, macular degeneration, antiangiogenic therapy, anti PDGF therapy, geographic atrophy, retinal degeneration, retinal transplant, stems cells, gene therapy, macular edema, and vitreoretinal and macular surgery.

4. INTERNATIONAL AWARDS:

4.1. Co-Winner of the INTERNATIONAL AWARD OF EXPERIMENTAL SURGERY Banc de Sabadell, Acadèmia de Medecina de Barcelona, i Col.legi Oficial de Metges de Barcelona, with the Research Project: "Photodynamic Therapy of the Experimental Posterior Malignant Melanoma" (Massachusetts Eye and Ear Infirmary, Harvard University, Boston, USA. Director of the Project: Evangelos Gragoudas MD). Barcelona, June 18, 1991.

4.2. Premi a la Recerca Científica en DMAE. Associació Discapacitat Visual de Catalunya. 30 Novembre 2011

4.3. Academy's Achievement Award 2015. American Academy of Ophthalmology.

C. Vitae Jordi Monés 6

5. ADVISORY BOARDS AND RESEARCH COMMITTEES

5.1. 1999: Rotating Member of Study Advisory Group of the “Randomized, Placebo-Controlled, Masked, Multicenter, Phase III b Study of the Treatment of the Subfoveal Neovascularization Secondary to Age-Related Macular Degeneration and pathologic myopia Using Photodynamic Therapy with Liposomal BPD-MA Verteporfin” Institut de Microcirurgia Ocular de Barcelona.

5.2. 2000: Rotating Member of Study Advisory Group of the “Photodynamic Therapy using Verteporfin Study VER, VIO and VIM”. Institut de Microcirurgia Ocular de Barcelona.

5.3. 2003: Member of the International Consultant Committee for Research in AMD, Novartis International, Basel, Switzerland.

5.4. 2003 – 2005: Member of the International Council for Research of Retinal Diseases of Eyetech Co. New York, USA

5.5. 2003 – Ongoing: Scientific Consultant of Notalvision, Co. Tel-Aviv, Israel.

5.6. 2003 – 2006: Member of the Macula Society Research Committee

5.7. 2008 Allergan advisory board. Annual Meeting Association for Research in vision and ophthalmology, Fort Lauderdale, USA. May 1-5 2008

5.8. 2008 Advisory Board Meeting Ophthotech for new treatments for exudative and Dry AMD London, 30 and 31 October, London

5.9. 2008 Advisory board Allergan for Posurdex device for the treatment of macular edema secondary to retinal vein occlusion and diabetic macular edema. American Academy of Ophthalmology, November 9. Atlanta, USA

5.10. 2008 Advisory Board for Preferential Hyperacuity Perimeter. Notalvision, Israel.

5.11. (from 2008 please see in section 13.2)

C. Vitae Jordi Monés 7

6. COLLABORATIVE EUROPEAN RESEARCH PROJECTS

6.1. 2013- 2016: LITE: Laser imaging Techniques for the anterior and posterior eye. Institut de Ciències Fotòniques; Istituto Nazionale di Ottica; Istituto di Fisica Applicata Nello Carrara, Construzione Strumenti Oftalmici and Institut de la Màcula i de la Retina (Principal investigator in Catalonia Site). ERANET Biophotonics. European Comission Financed

6.2. 2015-2016: PRO4VIP: Innovative PROcurement for Visually Impaired People. European Pre-Commercial Public Procurement (PCP) and Innovative Public Procurement (IPP) project that forms part of the European Vision 2020 strategy. Coordinated by AQuAS (Generalitat de Catalunya), it enjoys the participation of the Barcelona Macula Foundation, together with 12 other institutions from England, the rest of Spain, Denmark, France and Italy. Financed by H2020.

6.3. 2015-Ongoing: EYE RISK. Exploring the combined role of genetic and non- genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways (EYE-RISK). Topic PHC-01-2014. Horizon 2020. Coordinated by Eberhard Karls Universitaet Tuebingen (EKUT), it enjoys the participation of the Barcelona Macula Foundation, together with 10 other institutions. Financed by H2020.

6.4. 2016- On going. ADVANCE.CAT. Accelerating Development ON Advanced Teraphies in Catalonia. RIS3CAT communities. The research and innovation strategy of Catalonia. Generalitat de Catalunya. Financed by FEDER source.

7. BASIC RESEARCH PROJECTS

7.1. 2012 - 2016: Principal Investigator, The geographic atrophy in pig study (the GAP study): A phase I escalating dose of subretinal sodium iodate: a toxic- induced animal model of geographic atrophy of RPE and photoreceptors. Institut de la Màcula i de la Retina, Barcelona Macula Foundation

C. Vitae Jordi Monés 8

7.2. 2016- On going: Principal Investigator. Translational Research in regenerative stem cell therapies for retinal degenrative diseases from the swine animal model of retinal atrophy to clinical trials in human patients with age-related macular degeneration, retinitis pigmentosa and Stargardt’s disease. Barcelona Macula Foundation. Barcelona Macula Foundation (BMF), Centre de Medicina Regenerativa de Barcelona (CMRB), Banc de Sang i Teixitis (BSiT) and Fundación Leitat.

7. CLINICAL TRIALS

7.1. 1989: Principal Investigator of a multicentric, ranndomized, doble-masked clinical trial with 60 patients enrolled "Diclofenac colirio versus Dexametasona colirio en el Tratamiento de Estados Inflamatorios no Quirúrgicos del Segmento Anterior del Ojo sin Infección”. Centre d’Oftalmologia Barraquer.

7.2. 1997 - 2003: Principal Investigator of a “Randomized, Placebo-Controlled, Masked, Multicenter, Phase III Study of the Treatment of the Subfoveal Neovascularization Secondary to Age-Related Macular Degeneration Using Photodynamic Therapy with Liposomal BPD-MA Verteporfin”. Institut de Microcirurgia Ocular de Barcelona.

7.3. 1998 - 2002: Principal Investigator of a “Randomized, Placebo-Controlled, Masked, Multicenter, Phase III b Study of the Treatment of the Subfoveal Neovascularization Secondary to Age-Related Macular Degeneration and pathologic myopia Using Photodynamic Therapy with Liposomal BPD-MA Verteporfin”. Institut de Microcirurgia Ocular de Barcelona.

7.4. 2001 - 2004: Principal Investigator of the Study VER: “Multicenter, Randomized, Parallel Group, Double Mask, Controlled Phase IIIb, 2-year Study comparing the Efficacy and Safety of VISUDYNETM Therapy with Early Retreatment to Standard Treatment in Predominantly Classic Subfoveal Choroidal Neovascularization”. Institut de Microcirurgia Ocular de Barcelona.

7.5. 2001 - 2004: Principal Investigator of the Clinical Trial: “Eyetech Pharmaceuticals Phase II/III Clinical Trial with Anti-VRGF Pegylated Aptamer

C. Vitae Jordi Monés 9

(EYE001) in patients with Exudative Age-Related Macular Degeneration”. Institut de Microcirurgia Ocular de Barcelona

7.6. 2001: Principal Investigator of the Clinical Trial: Prospective Clinical Trial of VisionCare Ophthalmic Technologies Inc’s Implantable Miniature Telescope (IMTTM) for Patients with Age-Related Macular Degeneration” Institut de Microcirurgia Ocular de Barcelona.

7.7. 2003 - 2005: Principal Investigator of the Clinical Trial: “An Evaluation of Safety and Efficacy of Anecortave Acetate Sterile Suspension Following Sub- Tenon’s Injections for the Inhibition of Neovascularization in Patients With Exudative Age-Related Macular Degeneration”. Institut de Microcirurgia Ocular de Barcelona.

7.8. 2004 - 2005: Principal Investigator, Preferential Hyperacuity Perimetry Evaluation for Treatrment with Photodynamic Therapy of choroidal neovascularization. Institut de Microcirurgia Ocular de Barcelona.

7.9. 2005 - 2006: Co-Investigator, Estudio multicéntrico, fase III, enmascarado, aleatorizado, controlado con simulador, con una duración de 6 meses (con extensión abierta de 6 meses) para evaluar la seguridad y eficacia del sistema aplicador DEX PS DDS (Sistema de liberacion del fármaco dexametasona en el segmento posterior) de 700 microgr y 350 microgr en el tratamiento de pacientes con edema macular después de la oclusión de la vena central de la retina u oclusión de la rama de la vena central de la retina. Institut de Microcirurgia Ocular (IMO)

7.10. 2005 - 2006: Principal Investigator, “ENSAYO fase 3B, aleatorizado, controlado con tratamiento activo, doble ciego, con simulación simple, multicéntrico, comparativo y de grupos paralelos, para comparar la seguridad y la eficacia de inyecciones intravítreas de Macugen administradas cada 6 semanas durante 54 semanas (que pueden ampliarse hasta 102 semanas si está indicado) más terapia fotodinámica (TFD) simulada, frente a Macugen más TFD con VISUDYNE, en sujetos con neovascularización coroidea

C. Vitae Jordi Monés 10

(NVC) subfoveal predominantemente clásico secundaria a la degeneración macular relacionada con la edad (DMAE)” estudio 206207-009-00

7.11. 2005 - 2006: Co-investigator. VERTA V1. Institut de Microcirurgia Ocular (IMO), Novartis EudraCT: 2005-001324-36

7.12. 2005 - 2006: Principal Investigator, Evaluación internacional de la carga de enfermedad de la degeneración macular exudativa subfoveal asociada a la edad. Institut de Microcirurgia Ocular (IMO) Pfizer/ Covance SOA/COV 2627/ BC 100425

7.13. 2005: Principal Investigator, Estudio de fase III, multicéntrico, aleatorizado, controlado, con doble enmascaramiento de lactato de escualamina (MSI-1256F) en inyección para el tratamiento de la neovascularización coroidea subfoveal asociada a degeneración macular asociada a la edad. Institut de Microcirurgia Ocular (IMO), Genaera Corporation, MSI-1256F-302

7.14. 2005 -2006: Principal investigator. Ensayo de reducción de riesgo con acetoato de anecortave (AART) Evaluación de la eficacia y seguridad de la administración yuxtqexcleral posterior de acetato de anecortave para suspensión depot ( 15mg o 30mg ), comparado con la administración sdimulada en pacientes ( participantes en el estudi "A" o en esl estudio "B") con riesfgo de desarrollar neovasc coroidea (CNV ) con amenaza a la visión debido a degeneración macular asociada a la edad ( AMD ) Alcon C-02-60

7.15. 2005 - 2006: Pegaptanib en DMAE exudativa temprana comparada con DMAE exudativa no temprana.

7.16. 2005 - 2006: Ranibizumab Estudio EXCITE en DMAE exudativa

7.17. 2007 - 2009: Ongoing Promoter and Principal Investigator Raneovasc: ensayo clínico de fase ii, prospectivo, controlado, abierto, aleatorizado con grupos paralelos para comparar la seguridad y la eficacia del ranibizumab en monoterapia frente a la combinación con terapia fotodinámica con

C. Vitae Jordi Monés 11

verteporfina (TFDV) en pacientes con neovascularización coroidea (NVC) subfoveal secundaria a la degeneración macular asociada a la edad (DMAE)

7.18. 2008 – 2009: Principal Investigator Estudio de fase 3, aleatorizado, doble enmascarado, con asignación paralela de bevasiranib sódico intravítreo administrado cada 8 ó 12 semanas como terapia de mantenimiento tras 3 inyecciones de Lucentis®, comparado con monoterapia con Lucentis® cada 4 semanas en pacientes con Degeneración Macular Exudativa Asociada a la Edad. Promotor: OPKO Health.

7.19. 2008-2009: Co-investigator Estudio VIEW-2. Estudio de fase 3, randomizado, doble enmascarado, con grupo control, para evaluar la eficacia y seguridad de inyecciones intravítreas repetidas de VEGF-Trap en pacientes con degeneración macular asociada a la edad exudativa. Promotor: Bayer. Investigadors: Lluis Arias, Jordi Monés

7.20. 2008-2009: Co-investigator Estudio TG-MV-007. Estudio de fase 3, multicéntrico, con doble enmascaramiento, controlado con placebo y aleatorizado de la inyección intravítrea de microplasmina para el tratamiento no quirúrgico de la adherencia vitreomacular focal. Promotor: Thrombogenics. Investigadors: Lluis Arias, Jordi Monés

7.21. 2009: Principal investigator and protocol co-designer. A phase 1 study to establish the safety and tolerability of ARC1905 (anti-c5 aptamer) in subjects with dry age-related macular degeneration. Principal investigator: Jordi Monés. Co-investigators: Lluis Arias, Marc Biarnés.

7.22. 2010: Principal investigator and protocol co-designer: An open-labeL investigator research grant trial Phase II to establish the safety of intravitreous injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in NON RESPONDERS subjects with neovascular age-related macular degeneration. Protocol Number – E10030-001. Investigators: Jordi Monés

C. Vitae Jordi Monés 12

7.23. 2010: Principal investigator “Ensayo Fase II, randomizado, doble enmascarado, controlado, para establecer la seguridad y la eficacia de inyecciones intravítreas de E10030 (aptámero pegilado anti-PDGF) administrado en combinación con Lucentis® en sujetos con Degeneración Macular Asociada a la Edad forma Neovascular”. Protocolo nº OPH 1001

7.24. 2010 – Completed: Principal investigator principal & co-designer protocol – An open-label investigator research grant trial to establish the safety of intravitreous injections of E10030 (ANTI-PDGF aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration. Protocol E10030-001.

7.25. 2011 – Completed: Principal Investigator. Pilot phase II clinical trial to evaluate the safety of human fetal retinal transplant in the treatment of geographic secondary to age-related macular degeneration and retinitis pigmentosa. Institut de la Màcula i de la Retina, Barcelona Macula Foundation.

7.26. 2011- 2016: Principal Investigator and Steering committee member Crystal: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of individualized, stabilization criteria-driven pro re rata (PRN) dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy to patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). Promotor: Novartis. Institut de la Màcula i de la Retina, Barcelona Macula Foundation.

7.27. 2011- 2016: Principal Investigator and Steering committee member Brighter: A 24-month, phase IIIb, randomized, active-controlled, three-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria driven PRN dosing regimen with 0.5 mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein

C. Vitae Jordi Monés 13

occlusion (BRVO). Promotor: Novartis. Institut de la Màcula i de la Retina, Barcelona Macula Foundation.

7.28. 2013 - 2016: Principal Investigator. A phase II randomized, double- mask study to establish the safety and efficacy of high-dose oral Omega 3 in subjects with high-risk drusen secondary to dry age-related macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation.

7.29. 2013 – 2016: Principal Investigator. A phase II randomized, double- mask study to establish the safety and efficacy of high-dose oral Omega 3 in subjects with geographic secondary to dry age-related macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation.

7.30. 2012 - 2016: Principal Investigator, The MPL4 Drusen Study. a phase I study to establish the safety and efficacy of retinal pigment epithelium Micropulse Laser in subjects with high-risk drusen secondary to age-related macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation

7.31. 2012- 2016: Principal Investigator, The MPL4 Dry Study. A phase I study to establish the safety and efficacy of retinal pigment epithelium Micropulse Laser in subjects with geographic atrophy secondary to dry age- related macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation

7.32. 2013- 2015. Principal Investigator. Study Macbeth. Ensayo Clínico fase IV para evaluar la eficacia de Aflibercept en pacientes con degenración mcular ascoiada a la edad (DMAE) neovascular, sin respuesta óptima a repetidas inyecciones mensuales intravitreas de anti VEGFA. Promotor: Bayer.

7.33. 2014- 2016: Principal investigator. Eclipse. A phase 3 Randomized, doubled masked, controlled trial to establish the safety and efficay of intravitreous administrarion of FOVISTA (anti-PDGF-b pegylated aptamer)

C. Vitae Jordi Monés 14

administered in combination with Lucentis compared to Lucentis Monotherapy in subjects with suffoveal neovascular age-related macular degeneration. Multicenter clinical trial. Promotor:Ophthtech Parexel.

7.34. 2014- 2016: Principal Investigator. In Eye- Study. Ensayo Clínico en fase IV, abiero, aleatorizado, de 3 brazos, multicéntrico y de 12 meses de duración, para evaluar la eficacia y seguridad de dos régimenes de tratamiento, bimensual o PRN flexible individualizado de “tratar y extender”, versus un régimen PRN según citerios de establización mediante evaluaciones mensuales de inyecciones intravítreas de Ranibizumab 0.5mg en pacientes naive con neovascularización coroidea secundaria a la DMAE. Promotor: SERV.

7.35. 2014- 2015: Principal Investigator. Trend Study. Estudio fase IIIB multicentrico, randommizado, de 12 meses de seguimiento con evaluador de la agudeza visual enmascarado para evaluar la eficacia y la seguridad de Ranibizumab 0.5mg en un régimen de tratar y extender comparado con un régimen mensual, en pacientes con degeneración mcular neoovascular asociada a la edad. Promotor: Novartis.

7.36. 2014- 2016: Principal Investigator. Assessment of anatomical and functional outcomes in patients treated with ocriplasmin for vitreomacular traction/symptomatic vitreomacular adhesion. Multicenter trial. Promotor: Alcon.

7.37. 2014- 2016: Principal Investigator. Study MegaOmega4Dry. A phase II randomized, double-mask study to establish the safety and efficacy of High- dose oral Omega 3 in subjects with macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation.

7.38. 2015-2016: DARK. Deterioration of the Dark adaptation function in patients with drusen. Estudio Observacional Transversal. Institut De La Màcula and Barcelona Macula Foundation.

C. Vitae Jordi Monés 15

7.39. 2015-Ongoing: HARRIER (RTH258–C002). Estudi fase III, multicèntric, randomitzat, amb doble emmascarament de dos anys de durada que pretén avaluar l’eficàcia i la seguretat de RTH258 6 mg en comparació amb aflibercept (EYLEA) en subjectes amb DMAE exsudativa.

7.40. 2016- Ongoing. Omaspect. A multicenter, open-label extensión study to evaluate the long-term safety and tolerability of Lampalizumab in patients with GA secondary to AMD who have completed a Roche-sponsored study.

7.41. 2018- On going. Clinical trial OPH2005: Efficacy and safety of Zimura in the treatment of Stargardt’s disease.

8. GRANTS:

8.1. FUNDACIÓN RICH (Madrid, Spain): Year 1990, 1.700.000 ptas for 1 year of Vitreoretinal Researh Fellowship in the Massachusetts Eye and Ear Infirmary, Harvard University, Boston USA.

8.2. Beca FISS, Ministerio de Sanidad y Consumo. 1991.

9. SCIENTIFIC PUBLICATIONS:

9.1. Editor/Author Book:

9.1.1. Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla (eds) Barcelona, Prous Science, 2005.

9.2. Autor Book Chapters:

9.2.1. Monés i Carilla J, Friedman E: Angiografia coroidea con indocianina verde en la degeneración macular asociada con la edad. In: La Mácula Senil. Gómez-Ulla F (ed). Ciba Visión, Barcelona, 5: 75, 1993.

9.2.2. Monés JM, Guyer DR, Puliafito CP: Indocyanine green angiography.

C. Vitae Jordi Monés 16

In: Principles and Practice of Ophthalmology. Albert DM, Jakobiec FA (eds). Philadelphia, WB Saunders, (2) 52: 718, 1994.

9.2.3. Monés i Carilla J: Videoangiografía con indocianina verde mediante Scanning Laser Ophthalmoscope: Generalidades. In: Nuevos Métodos de Exploración retiniana. Gómez-Ulla F (ed). Sociedad Española de Oftalmología, Madrid, 3: 37, 1994.

9.2.4. Monés i Carilla J: Videoangiografía con indocianina verde mediante Scanning Laser Ophthalmoscope en la DMAE. In: Nuevos Métodos de Exploración retiniana. Gómez-Ulla F (ed). Sociedad Española de Oftalmología, Madrid, 6: 67, 1994.

9.2.5. Monés JM, Slakter J: Indocyanine Videoangiography in Serpiginous Choroidopathy. IN: Indocyanine Green Angiography. Yannuzzi LA, Flowe RW, Slakter JS. St. Louis, Mosby, (17): 247, 1997.

9.2.6. Monés JM. Luxación posterior de lentes intraoculares. In: Corcóstegui B (Eds) Sociedad Española de Oftalmología. Torremolinos, September 1999

9.2.7. Monés JM, Guyer DR, Puliafito CP: Indocyanine green angiography. In: Principles and Practice of Ophthalmology. 2nd edition Albert DM, Jakobiec FA (eds). Philadelphia, WB Saunders, (2) 52: 718, 1999.

9.2.8. Monés JM. PDT for miopía. In: Photodynamic Therapy of Ocular Diseases. Gragoudas ES, Miller JW, Zografos L (eds). Lippincot, Williams & Wilkins. Philadelplhia

9.2.9. Monés JM, Loewenstein A. Perimetría de Hiperagudeza Preferencial. In: Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla (eds) Barcelona, Prous Science, 2005.

9.2.10. Arias L, Monés JM. Terapia Fotodinámica em DMAE. In: Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla (eds) Barcelona, Prous Science, 2005.

C. Vitae Jordi Monés 17

9.2.11. Mateo C, Pérez Belmonte L, Navarro R, Monés J. Translocación macular. In: Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla (eds) Barcelona, Prous Science, 2005.

9.2.12. Monés JM, Guyer DR, Puliafito CP. Indocyanine green angiography. In: Principles and Practice of Ophthalmology. Albert DM, Jakobiec FA (eds). 2nd edition Philadelphia, WB Saunders, 2007

9.2.13. Fundus autofluorescence patterns and optical coherence tomography in geographic atrophy secondary to AMD"AMD. Revision book". Silva R et al. Ed Théa, 2010 (at the publisher)

9.2.14. Jonas J, Paques M, Monés J, Glacet-Bernard A. Retinal Vein Occlusion. Macular Edema. Ed. Gab riel Coscas (at the publisher)

9.2.15. Loewenstein A, Zur D, Tufail A, Monés J. Postsurgical cystoid macular edema. Retinal Vein Occlusion. Macular Edema. Ed. Gabriel Coscas (at the publisher)

9.3. Spanish Scientific Journals:

9.3.1. Vilaplana i Blanch D, Soler i Tomàs JR, Monés i Carilla JM, Sena i Dutrenit JM. Profilaxis del desprendimiento de la retina. Fotocoagulación con làser. Revista d'Or d'Oftalmologia, 1988.

9.3.2. Soler i Tomàs JR, Vilaplana i Blanch D, Monés i Carilla JM, Sena i Dutrenit JM. Estudio comparativo làser Argon versus Krypton rojo en el tratamiento de la coroidorretinopatía central serosa. Revista d'Or d'Oftalmologia, 1989.

9.4. International Scientific Journals:

9.4.1. Monés JM, Woods WJ, Puliafito CA. Retinal toxicity of hyaluronidase and thimerosal injected into the vitreous body of the rabbit. Invest

C. Vitae Jordi Monés 18

Ophthalmol Vis Sci 32 (4) (Suppl): 879, 1991.

9.4.2. Bauman WC, Monés JM, Tritten JJ, Lin CP, Gragoudas E, Puliafito CA. Transpupillary phthalocyanine photodynamic therapy of experimental posterior malignant melanoma. Invest Ophthalmol Vis Sci 32 (4) (Suppl): 713, 1991.

9.4.3. Puliafito CA, Guyer DR, Monés JM, Weaver Y. Indocyanine-Green Digital Angiography and Dye-Enhanced Diode Laser Photocoagulation of Choroidal Neovascularization. Invest Ophthalmol Vis Sci 32 (4) (Suppl): 712, 1991.

9.4.4. Guyer DR, Puliafito CA, Monés JM, et al. Indocyanine-green digital angiography in chorioretinal disorders. Ophthalmol 99: 287, 1992.

9.4.5. Corcóstegui B, Monés JM. Indocyanine videangiography with Scanning Laser Ophthalmoscope of large choroidal vessels in exudative age- related macular degeneration. Invest Ophthalmol Vis Sci 35 (4) (Suppl): 1507, 1994.

9.4.6. Monés J and the VIP Study Group. Photodynamic therapy (PDT) with Verteporfin of subfoveal choroidal neovascularization in age-related macular degeneration: Study design and baseline characteristics in the VIP randomized clinical trial. Invest Ophthalmol Vis Sci 40 (4) (Suppl): 1703 1999.

9.4.7. TAP Study Group (Jordi Monés is the writing Committee). Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin. One-Year Results of 2 Randomized Clinical Trials – TAP Report 1. Arch Ophthalmol 1999; 117: 1329 – 1345.

9.4.8. TAP Study Group (Jordi Monés as is the writing Committee). Case series of VA improvements following PDT with Verteporfin fon CNV in

C. Vitae Jordi Monés 19

AMD (In preparation)

9.4.9. TAP Study Group (Jordi Monés as is the writing Committee). Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001 Feb;119(2):198-207.

9.4.10. VIP Study Group (Jordi Monés as is the writing Committee). Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia with Verteporfin. Two-year Vision Results of 2 Randomized Clinical Trials. VIP report 1. Ophthalmology 2001 May;108(5):841-852

9.4.11. VIP Study Group (Jordi Monés as is the writing Committee). Verteporfin Therapy of Subfoveal choroidal neovascularization in age- related macular degeneration: two-year results of a randomised clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001 May, 131 (5): 541-560.

9.4.12. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators; Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002 Feb;22(1):6-18.

9.4.13. VIP Study Group (Jordi Monés as is the writing Committee). Letter to the Editor of the American Journal of Ophthalmology regarding additional data relevant to VIP Report 2.

9.4.14. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C,

C. Vitae Jordi Monés 20

Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age- Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol. 2002 Oct;120(10):1307-14.

9.4.15. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol. 2002 Nov;120(11):1443-54

9.4.16. Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P, Schachat AP, Strong HA, Wenkenstern A; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol. 2003 Sep;121(9):1253-68

9.4.17. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report

C. Vitae Jordi Monés 21

no. 3. Ophthalmology. 2003 Apr;110(4):667-73.

9.4.18. TAP Study Group (Jordi Monés as is the writing Committee). Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G; Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age- related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003 Sep;136(3):407-18

9.4.19. Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB, Gragoudas ES, Fish GE, Hao Y, Haynes L, Lim JI, Menchini U, Miller JW, Monés J, Potter MJ, Reaves A, Rosenfeld PJ, Strong A, Su XY, Slakter JS, Schmidt-Erfurth U, Sorenson JA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study GroupVerteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study. Report no. 4. Retina. 2004 Feb;24(1):1-12.

9.4.20. (Jordi Monés as in the Writing Committee). Pegaptanib for Neovascular Age-Related Macular Degeneration. Evangelos S. Gragoudas, M.D., Anthony P. Adamis, M.D.,Emmett T. Cunningham, Jr., M.D., Ph.D., M.P.H., Matthew Feinsod, M.D.,and David R. Guyer, M.D., for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. n engl j med 351;27 www.nejm.org December 30, 2004

9.4.21. Monés J, Rubin GS. Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to

C. Vitae Jordi Monés 22

age-related macular degeneration. Eye (Lond). 2005 Nov;19(11):1142-50. Review.

9.4.22. TAP Study Group (Jordi Monés as in the writing Committee). Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age- Related Macular Degeneration: Four-Year Results of an Open-Label Extension of 2 Randomized Clinical Trials: TAP Report No. 7 Arch Ophthalmol. 2005;123:1283-1285.

9.4.23. Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot- Garcher C, Dimitrakos SA 2nd, Korobelnik JF, Larsen M, Monés J, Pauleikhoff D, PournarasCJ, Staurenghi G, Virgili G, Wolf S. Evolving European guidance on the medical management of neovascular age related macular degeneration.Br J Ophthalmol. 2006 Sep;90(9):1188-96.

9.4.24. Monés J. New perspectives on the treatment of age-related macular degeneration. Drugs Today (Barc). 2005 Nov;41(11):701.

9.4.25. Monés JM, Lopez MA, Prieto JA, Rodriguez JP.Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab.Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):226-8.

9.4.26. Monés J [Bevacizumab or Ranibizumab, or the tale of Robin Hood and King Richard Lion Heart.]Arch Soc Esp Oftalmol. 2007 Sep;82(9):529-30. Spanish. No abstract available. PMID: 17846939 [PubMed - in process]

9.4.27. Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monés J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol. 2007 Sep;125(9):1249- 54.

9.4.28. Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery

C. Vitae Jordi Monés 23

A, Monés J, Buggage R, Schaefer C, Knight T, Goss TF. Economic burden of bilateral neovascular age-related macular degeneration: multi- country observational study. Pharmacoeconomics. 2008;26(1):57-73.

9.4.29. Monés J, Amselem L, Serrano A, García M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye. 2009 Jun;23(6):1275-80

9.4.30. Amselem L, Pulido JS, Gunduz K, García-Arumí J, Monés J. Infrared reflectance in choroidal melanomas and its correlation with fundus autofluorescence. Br J Ophthalmol. 2008 Nov;92(11):1565-6. [Pubmed]

9.4.31. Ruiz-Moreno JM, Arias-Barquet L, Armadá-Maresca F, Boixadera-Espax A, García-Layana A, Gómez-Ulla-de-Irazazábal F, Monés-Carilla J, Piñero-Bustamante A, Suárez-de-Figueroa M. [Guidelines of clinical practice of the SERV: treatment of exudative age- related macular degeneration (AMD)] Arch Soc Esp Oftalmol. 2009 Jul;84(7):333-44.

9.4.32. Arias L. Monés J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. Clinical Ophthalmology 2010: 4 67-72

9.4.33. Arias L, Monés J. Ranibizumab in the treatment of choroidal neovascularization on the border of an inferior staphyloma associated with tilted disc syndrome. Clin Ophthalmol. 2010 Apr 26;4:227-31.

9.4.34. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. ( Jordi Monés as in the GENEVA Study Group). Randomized, sham-controlled trial of dexamethasone

C. Vitae Jordi Monés 24

intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010 Jun;117(6):1134-1146.e3. Epub 2010 Apr 24

9.4.35. Jonas J, Paques M, Monés J, Glacet-Bernard A. Retinal vein occlusions. Dev Ophthalmol. 2010;47:111-35. Epub 2010 Aug 10. Review.

9.4.36. Biarnés M, Monés J, Villalbí JR, Arias L. As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration. Eur J Ophthalmol. 2011 May-Jun;21(3):282-9. doi: 10.5301/EJO.2010.5766. PMID: 20890885 [PubMed - indexed for MEDLINE]

9.4.37. Monés J. A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related Macular Degeneration and How to Translate It into Daily Practice. Ophthalmologica. 2011;225(2):112-9. doi: 10.1159/000319906. Epub 2010 Oct 8.

9.4.38. Zur D, Fischer N, Tufail A, Monés J, Loewenstein A.Postsurgical cystoid macular edema. Eur J Ophthalmol. 2011;21 Suppl 6:S62-8. doi: 10.5301/EJO.2010.6058.

9.4.39. Biarnés M, Monés J, Arias L, Villalbí JR. An Update on Geographic Atrophy in Age-Related Macular Degeneration Optometry and Vision Science. Optometry and Vision Science. Optom Vis Sci. 2011 Apr 28. [Epub ahead of print]

9.4.40. Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia M, Lanzetta P, Monés J, de Smet M, Soubrane G, Staurenghi G. Management of Retinal Vein Occlusion – Consensus Document. Ophthalmologica 2011;226:4-28.

9.4.41. Biarnés M, Monés J, Trindade F, Alonso J, Arias L. Intra and interobserver agreement in the classification of fundus autofluorescence

C. Vitae Jordi Monés 25

patterns in geographic atrophy secondary to age-related macular degeneration Graefes Arch Clin Exp Ophthalmol. 2012 Apr;250(4):485- 90. Epub 2011 Oct 28.

9.4.42. Monés J, Biarnés M, Trindade F. Hyporeflective wedge-shaped band in geographic atrophy secondary to age-related macular degeneration: an underreported finding. Ophthalmology. 2012 Jul;119(7):1412-9. Epub 2012 Mar 21.

9.4.43. Monés J, Biarnés M, Trindade F, Casaroli-Marano R. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age- related macular degeneration and relatively good baseline visual acuity. Graefes Arch Clin Exp Ophthalmol. 2012 Dec;250(12):1737-44. Epub 2012 Apr 15.

9.4.44. Monés J, Biarnés M, Trindade F, Arias L, Alonso J. Optical Coherence Tomography Assessment of Apparent Foveal Swelling in Ophthalmology. 2013 Apr;120(4):829-36. doi: 10.1016/j.ophtha.2012. 09.054. Epub 2013 Jan 3.

9.4.45. L. Arias Barquet and J. Monés. New treatment protocols and follow-up in patients with exudative age-related macular degeneration. Archivos de la Sociedad Española de Oftalmología. Volume 87. Supplement 1. December 2012.

9.4.46. Lanzetta P. Holz F. Monés J. Querques G. Stanga P. Veritti D. Barbone F. Brusaferro S. Isola M. Intravitreal Injections: A Healthcare Failure Modes and Effects Analysis. Ophthalmologica (DOI: 10.1159/000354549).

9.4.47. Monés J, Biarnés M, Badal J. Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case

C. Vitae Jordi Monés 26

report. Clin Ophthalmol. 2013;7:1089-92. doi: 10.2147/OPTH.S45155. Epub 2013 Jun 7.

9.4.48. Monés J. as a participant of a round table of participant leaders. Advocating for Improved treatment and Outcomes for Wet Age-retaled Macular Degeneration. A report based on an International Expert Summit. Convened in Berlin, Germany November 2011. The Angiogenesis Foundation.

9.4.49. Alfredo García-Layana, Luis Arias, Marta S. Figueroa, Monés J. Araiz, José María Ruiz-Moreno, José Garcia-Aruní, Francisco Gómez- Ulla, María Isabel López-Gálvez, Francisco Cabrera-López, José Manuel García Campos, Jordi Monés, Enrique Cervera, Félix Armadá, Miguel Ángle Serrano, Juan Donate, Roberto Gallego-Pinazo. Guía clínica de Expertos sobre el Manejo de la Degeneración Macular Asociada a la Edad Exudativa. Revista Española de Patología Macular. Volumen IV. Nº4. Noviembre de 2013.

9.4.50. Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein, Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi Monés, Gisbert Richard and Francesco Bandello. “Guidelines for the management of neovascular age-related macular degeneration” by the European Society of Retina Specialists (EURETINA). The British journal of ophthalmology 09/2014; 98(9):1144-1167. DOI: 10.1136/bjophthalmol- 2014-305702

9.4.51. Biarnés M, Forero CG, Arias L, Alonso J, Monés J. Reappraisal of geographic atrophy patterns seen on fundus autofluorescence using a latent class analysis approach. Invest Ophthalmol Vis Sci. 2014 Nov 18. pii: IOVS-13-13542. doi: 10.1167/iovs.13-13542. [Epub ahead of print].

9.4.52. Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K; FAME Study Group. Monés J. as a collborator. Sustained delivery fluocinolone acetonide vitreous implants:

C. Vitae Jordi Monés 27

long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1892-903. doi: 10.1016/j.ophtha.2014.04.019. Epub 2014 Jun 14.

9.4.53. Boyer DS, Goldbaum M, Leys AM, Starita C; V.I.S.I.O.N. Study Group. Monés J as a collaborator. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. Br J Ophthalmol. 2014 Nov;98(11):1543-6. doi: 10.1136/bjophthalmol-2013-304075. Epub 2014 Jul 4.

9.4.54. Gerding H, Monés J, Tadayoni R, Boscia F, Pearce I, Priglinger S. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. Br J Ophthalmol. 2014 Jul 29. pii: bjophthalmol-2014- 305041. doi: 10.1136/bjophthalmol-2014-305041. [Epub ahead of print]

9.4.55. García-Layana A, Arias L, Figueroa MS, Araiz J, Ruiz-Moreno JM, García-Arumí J, Gómez-Ulla F, López-Gálvez MI, Cabrera-López F, García-Campos JM, Monés J, Cervera E, Armadá F, Gallego-Pinazo R, Piñero-Bustamante A, Serrano-Garcia M. A delphi study to detect deficiencies and propose actions in real life treatment of neovascular age- related macular degeneration. J Ophthalmol. 2014;2014:595132. doi: 10.1155/2014/595132. Epub 2014 Dec 21.

9.4.56. Biarnés M, Arias L, Alonso J, Garcia M, Hijano M, Rodríguez A, Serrano A, Badal J, Muhtaseb H, Verdaguer P, Monés J. Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study. Am J Ophthalmol. 2015 Aug;160(2):345-353.e5. doi:10.1016/j.ajo.2015.05.009. Epub 2015 May 15. PMID: 25982972

9.4.57. Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Monés J, Regillo

C. Vitae Jordi Monés 28

C, Tadayoni R, Talks J, Wolf S. Treat-And-Extend Regimens With Anti- Vegf Agents in Retinal Diseases: A Literature Review and Consensus Recommendations. Retina. 2015 Jun 12. [Epub ahead of print]

9.4.58. Dr. Jordi Monés, Dr. Josep Badal, Dr. Marc Biarnés. Feeder Vessel Laser Photocoagulation For Idiopathic, Subfoveal Polypoidal Choroidal Vasculopathy Not Responding To Either Anti-Vascular Endothelial Growth Factor Therapy Or Photodynamic Therapy. Retin Cases Brief Rep. 2016 Winter;10(1):100-3. doi: 10.1097/ICB.0000000000000174.

9.4.59. Richard G, Monés J, Wolf S, Korobelnik JF, Guymer R, Goldstein M, Norenberg C, Sandbrink R, Zeitz O. Scheduled versus Pro Re Nata Dosing in the VIEW Trials. Ophthalmology. 2015 Dec;122(12):2497-503. doi: 10.1016/j.ophtha.2015.08.014. Epub 2015 Oct 21. PMID: 26477840

9.4.60. Alfredo García-Layana, Marta S. Figueroa, Luis Arias, Javier Araiz, José María Ruiz-Moreno, José García-Arumí, Francisco Gómez- Ulla, María Isabel López-Gálvez, Francisco Cabrera-López, José Manuel García-Campos, Jordi Monés, Enrique Cervera, Felix Armadá, and Roberto Gallego-Pinazo. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. Journal of Ophthalmology, vol. 2015, Article ID 412903, 8 pages, 2015. doi:10.1155/2015/412903.

9.4.61. Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S, Stubbings W, Pearce I; CRYSTAL Study Group. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study. Ophthalmology. 2016 May;123(5):1101-11. doi: 10.1016/j.ophtha.2016.01.011. Epub 2016 Feb 17.

C. Vitae Jordi Monés 29

9.4.62. Monés J, Biarnés M. Correspondence. Retina. 2016 Mar;36(3):e20. doi: 10.1097/IAE.0000000000000944. No abstract available.

9.4.63. Marc Biarnés, PhD; Jordi Monés, MD, PhD. Direct Visualization of a New Choroidal Vessel on Spectral-Domain Optical Coherence Tomography. Ophthalmic Images | March 10, 2016. JAMA Ophthalmol. 2016;134(3):e155017. doi:10.1001/jamaophthalmol.2015.5017.

9.4.64. Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S, Wenzel A, Barnes E, Gekkieva M, Pilz S, Monés J; BRIGHTER study group. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER. Ophthalmology. 2016 Jun;123(6):1332-44. doi: 10.1016/j.ophtha.2016.02.030. Epub 2016 Mar 30.

9.4.65. Monés J, Leiva M, Peña T, Martínez G, Biarnés M, Garcia M, Serrano A, Fernandez E. A Swine Model of Selective Geographic Atrophy of Outer Retinal Layers Mimicking Atrophic AMD: A Phase I Escalating Dose of Subretinal Sodium Iodate. Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):3974-83. doi: 10.1167/iovs.16-19355. PMID: 27479813

9.4.66. Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, Masonson H, Monés J, Pearlman JA, Quaranta-El Maftouhi M, Ricci F, Westby K, Patel SC. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. Ophthalmology. 2017 Feb;124(2):224-234. doi: 10.1016/j.ophtha.2016.10.010. PMID: 28029445

9.4.67. Holz FG, Sadda SR, Staurenghi G, Lindner M, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Curcio CA, Danis R, Fleckenstein M, Freund KB, Grunwald J, Guymer R, Hoyng CB, Jaffe GJ, Liakopoulos S, Monés JM, Oishi A, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Schmitz-Valckenberg S;

C. Vitae Jordi Monés 30

CAM group. Imaging Protocols in Clinical Studies in Advanced Age- Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. Ophthalmology. 2017 Jan 18. pii: S0161- 6420(16)30920-4. doi: 10.1016/j.ophtha.2016.12.002. [Epub ahead of print] PMID: 28109563

9.4.68. Badal J, Biarnés M, Monés J. Performance characteristics of multicolor versus blue light and infrared imaging in the identification of reticular pseudodrusen. Int Ophthalmol. 2017 Jan 21. doi: 10.1007/s10792-017-0448-z. [Epub ahead of print] PMID: 28108901

9.4.69. Monés, J., Garcia, M., Biarnés, M., Lakkaraju, A., & Ferraro, L. (2017). Drusen Ooze: A Novel Hypothesis in Geographic Atrophy. Ophthalmology Retina. Ophthalmology Retina 2017;-:1e13 ª 2017 by the American Academy of Ophthalmology.

9.4.70. Monés J, Biarnés M. Geographic atrophy phenotype identification by cluster analysis. British Journal of Ophthalmology. Published Online First: 20 July 2017. doi: 10.1136/bjophthalmol-2017- 310268

9. SCIENTIFIC PRESENTATIONS:

9.1. Spanish Meetings:

9.1.1. Monés i Carilla JM, Ruiz Bulumar JL.: "Uso de la Mezlocilina tópica en el Tratamiento del Absceso Corneal por Pseudomonas". "LXIII CONGRESO NACIONAL DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA". Oviedo, September 1987.

9.1.2. Monés JM: "Lesiones predisponentes. Profilaxis del desprendimiento de la retina". "III CURSO DEL DESPRENDIMIENTO DE RETINA Y

C. Vitae Jordi Monés 31

VITREO. INSTITUTO CASTANERA". Barcelona, October 1987.

9.1.3. Monés i Carilla JM, Rodriguez i Prats JL, Iglesias i Touriño E: "Afectació Ocular en la Neurofibromatosi de Von Reckinghausen". "VII JORNADES MÈDIQUES DEL VALLÈS. ACADÈMIA DE CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS". Sabadell, November 1987.

9.1.4. Monés i Carilla JM, Soler i Tomàs JR, Iglesias i Touriño E: "Tractament de l'Abscés Cornial Bacterià Resistent als Antibiòtics Convencionals". "VII JORNADES MÈDIQUES DEL VALLÈS. ACADÈMIA DE CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS". Sabadell, November 1987.

9.1.5. Vilaplana i Blanch D, Soler i Tomàs JR, Monés i Carilla JM, Sena i Dutrenit JM: "Fotocoagulació Làser en la Profilaxi del Desprendiment de la Retina". "VII JORNADES MÈDIQUES DEL VALLÈS. ACADÈMIA DE CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS". Sabadell, November 1987.

9.1.6. Monés i Carilla, JM, Samaan M: "Goniotomía ab interno y trabeculotomía ab externo con trabeculectomía". "LXIV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA". Palma de Mallorca, October 1988.

9.1.7. Monés J, Corcóstegui B: "Videoangiografia amb indocianina verda - oftalmoscopi de làser d'scanning (VICV - SLO) en la degeneració macular associada a l'edat (DMAE) forma exudativa." "NOVES TÉCNIQUES D'EXPLORACIÓ I DIAGNÒSTIC EN OFTALMOLOGIA". La Seu D'Urgell, April 1994.

9.1.8. Monés J, Corcóstegui B: " Videoangiografia amb indocianina verda - oftalmoscopi de làser d'scanning (VICV - SLO). Estudi i diagnòstic de les malalties inflamatòries coroidals." "NOVES TÉCNIQUES D'EXPLORACIÓ I DIAGNÒSTIC EN OFTALMOLOGIA". La Seu

C. Vitae Jordi Monés 32

D'Urgell, April 1994.

9.1.9. Monés J, García Arumí J, Adán A: "Estudio y diagnóstico de las coroiditis mediante la videongiografía indocianina verde - SLO." "LXX CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Tenerife, September 1994.

9.1.10. Monés J, Mateo C, Corcóstegui B: "Detección y clasificación de las membranas neovasculares coroideas en la DMAE mediante videoangiografía ICV - SLO. "LXX CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Tenerife, September 1994.

9.1.11. Monés J, Corcóstegui B, Durán N: "Patrones cicrculatorios coroideos submaculares en la DMAE." "LXX CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Tenerife, September 1994.

9.1.12. Monés J, Corcóstegui B: "Efecte a distància de la fotocoagulació amb làser de diode: una complicació o una estratègia terapeútica?" "25è CONGRÉS DE LA SOCIETAT CATALANA D'OFTALMOLOGIA". Barcelona, December 1994.

9.1.13. Jordi Monés, Andreu Coret: “Técnica combinada de implante secundario de LIO de cámara posterior por incisión corneal con vitrectomía pars plana y fijación transescleral”. “III CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO”. Madrid, February 21-22, 1997.

9.1.14. Jordi Monés, Andreu Coret, Josep Ramon Soler: “Recolocación interna con fijación escleral de LIO luxada a cámara vítrea mediante vitrectomía posterior”. “III CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO”. Madrid, February 21-22, 1997.

9.1.15. Jordi Monés i Carilla, Andreu Coret Novoa: “ Técnica combinada de cirugía del agujero macular y facoemulsificación e implante de LIO

C. Vitae Jordi Monés 33

de CP” “12º CONGRESO SECOIR”. Santander, April 23-26, 1997.

9.1.16. Jordi Monés i Carilla, Josep Ramon Soler i Tomás: “ Técnica de implante 2ºde LIO-CP con fijación transescleral mediante vitrectomía posterior.” “12º CONGRESO SECOIR”. Santander, April 23-26, 1997

9.1.17. J. Monés, F. Huste, IH Tercero: “Tècnica d’implant secundari de LIO amb fixació transescleral amb vitrectomia posterior” “4ª BIENNAL DE VIDEO OFTALMOLOGIA”. Girona, June 28, 1997.

9.1.18. J. Monés, JR Soler Tomàs, JA Cardona: “Tècnica combinada de cirurgia de forat macular i facoemulsificació i implant de LIO-CP” “4ª BIENNAL DE VIDEO OFTALMOLOGIA”. Girona, June 28, 1997.

9.1.19. Jordi Monés Carilla, Andrés Coret. “Recolocación interna de LIO luxada a cámara vítrea mediante vitrectomía posterior y fijación transecleral. LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Granada, September 24-28, 1997.

9.1.20. José Ramon Soler Tomás, Jordi Monés Carilla. “Técnica combinada de cirugía de agujero macular y facoemulsificación de la catarata con implante plegable de cámara posterior”. LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Granada, September 24-28, 1997.

9.1.21. Jordi Monés Carilla. “Vitrectomía posterior sin suturas” 74 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Alicante, September 30 - October 4, 1998.

9.1.22. Jordi Monés i Carilla “Técnica de reparación inmediata de luxación de núcleo durante la facoemulsificación: vitrectomía posterior e implante de lente intraocular con fijación escleral a través de pequeña incisión”. 74 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Alicante, 30 Sept - Oct 4, 1998.

C. Vitae Jordi Monés 34

9.1.23. Jordi Monés: “Terapia Fotodinámica en DAME exudativa: Resultados de pacientes en Uso compasivo.” ” 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, 11-15 October, 2000.

9.1.24. Jordi Monés I cols. Teràpia Fotodinàmica en DMAE: resultants de pacients en Fase d’ús Compassiu. 31 CONGRÉS DE LA SOCIETAT CATALANA D’OFTALMOLOGIA”. Barcelona, 23-24 November 2000.

(PRESENTATIONS and LECTURES are presented together from this point in the section 11.2)

9.2. International Meetings:

9.2.1. Sena Dutrenit JM, Vilaplana D, Soler JR, Monés JM: "Resultados de la Fotocoagulación Láser". "IX CURS INTERNACIONAL D'OFTALMOLOGIA DEL INSTITUT BARRAQUER". Barcelona, May 1987.

9.2.2. David R. Guyer, Carmen A. Puliafito, Jordi M. Monés: "Indocyanine-Green Digital Angiography and Dye-Enhanced Diode Laser Photocoagulation of Choroidal Neovascularization". "ADVANCES IN OCULAR DRUG THERAPY: A PRACTICAL PERSPECTIVE. Massachusetts Eye and Ear Infirmary. Harvard Medical School. Boston, Massachusetts. USA, March 9, 1991.

9.2.3. David R. Guyer, Carmen A. Puliafito, Jordi M. Monés: "Indocyanine-Green Digital Angiography and Dye-Enhanced Diode Laser Photocoagulation of Choroidal Neovascularization". "1991 WILMER RESIDENTS ASSOCIATION MEETING". THE Wilmer Institute. John Hopkins University, School of Medicine. Baltimore, Maryland. USA. April 25-27, 1991.

9.2.4. Wendall C. Bauman, Jordi M. Monés, Jean-Jacques Tritten, Charles P. Lin, Evangelos Gragoudas, Carmen A. Puliafito: "Transpupillary

C. Vitae Jordi Monés 35

Phthalocyanine Photodynamic Therapy of Experimental Posterior Malignant Melanoma". "1991 ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. April 28 - May 2, 1991.

9.2.5. Jordi M. Monés, William J. Woods and Carmen A Puliafito: "Retinal Toxicity of Hyaluronidase and Thimerosal injected into the Vitreous Body of the Rabbit". "1991 ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. April 28 - May 2, 1991.

9.2.6. Carmen A. Puliafito, David R. Guyer, Jordi M. Monés, Yaffa Weaver: "Indocyanine-Green Digital Angiography and Dye-Enhanced Diode Laser Photocoagulation of Choroidal Neovascularization". "1991 ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. April 28-May 2, 1991.

9.2.7. Ephraim Friedman, Jordi M. Monés: "The use of Indocyanine-Green in evaluating the Choroidal Circulation". "MASSACHUSETTS EYE AND EAR ALUMNI ASSOCIATION. ANNUAL CLINICAL AND SCIENTIFIC MEETING". Boston, Massachusetts. USA. May 16,1991.

9.2.8. David R. Guyer, Carmen A. Puliafito, Jordi M. Monés: "Indocyanine-Green Dye Enhanced Diode Laser Photocoagulation of Choroidal Neovascularization". "MASSACHUSETTS EYE AND EAR ALUMNI ASSOCIATION. ANNUAL CLINICAL AND SCIENTIFIC MEETING". Boston, Massachusetts. USA. May 16,1991.

9.2.9. Wendall C. Bauman, Jean-Jacques Tritten, Jordi M. Monés, Charles P. Lin, Evangelos Gragoudas, Carmen A. Puliafito: "Transpupillary PhotodynamicTherapy of Experimental Malignant Melanoma".

C. Vitae Jordi Monés 36

"MASSACHUSETTS EYE AND EAR ALUMNI ASSOCIATION. ANNUAL CLINICAL AND SCIENTIFIC MEETING". Boston, Massachusetts. USA. May 16,1991.

9.2.10. Jordi M. Monés, David R. Guyer, Carmen A. Puliafito, Ephraim Friedman. "Indocyanine-Green Angiography in Choroidal Diseases". "1991 SCHEPENS INTERNATIONAL SOCIETY MEETING". Madrid, May 27-31, 1991.

9.2.11. Jordi M. Monés, Wendall C. Bauman, Jean-Jacques Tritten, Charles P. Lin, Carmen A. Puliafito, Evangelos Gragoudas: "Phthalocyanine Photodynamic Treatment of Experimental Posterior Malignant Melanoma". "1991 SCHEPENS INTERNATIONAL SOCIETY MEETING". Madrid, May 27- 31, 1991.

9.2.12. Carmen A. Puliafito, David R. Guyer, Jordi M. Monés: "Digital Indocyanine-Green Angiography in retinal vascular diseases". "1991 ANNUAL MEETING OF THE AMERICAN ACADEMY OF OPHTHALMOLOGY". Anaheim, California. USA. October 13-17, 1991.

9.2.13. Corcóstegui B, Monés JM: "Indocyanine videangiography with Scanning Laser Ophthalmoscope of large choroidal vessels in exudative age-related macular degeneration." "1994 ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. May 1-6, 1994.

9.2.14. Jordi M. Monés, Borja Corcóstegui: "Submacular choroidal vascular patterns in exudative age-related macular degeneration." "4th INTERNATIONAL SYMPOSIUM ON OCULAR CIRCULATION AND NEOVASCULARIZATION". Budapest, Hungary, May 22-26, 1995.

9.2.15. Jordi Monés i Carilla, Josep Ramon Soler i Tomàs: “Implante secundario con fijación transescleral mediante Vitrectomía Posterior” “CURSO INTERNACIONAL INSTITUTO BARRAQUER”. Barcelona,

C. Vitae Jordi Monés 37

June 9-11, 1997.

9.2.16. Jordi Monés, Andreu Coret, Josep Ramon Soler: “Recolocación interna con fijación escleral de LIO luxada a cámara vítrea mediante vitrectomía posterior”. “CURSO INTERNACIONAL INSTITUTO BARRAQUER”. Barcelona, June 9-11, 1997.

9.2.17. JR Soler Tomàs, J Monés, A Cardona, F. Huste: “Anillos intracapsulares de tensión. Aplicaciones” “CURSO INTERNACIONAL INSTITUTO BARRAQUER”. Barcelona, June 9-11, 1997.

9.2.18. Monés JM: Pars plana vitrectomy and scleral fixation of foldable intraocular lens through small incision during complicated pahcoemulsification of dense cataract with intravitreal nuclear fragments luxation. XVIth CONGRESS OF THE ESCRS. Nice, September 6-9, 1998.

9.2.19. Monés J and the VIP Study Group. Photodynamic therapy (PDT) with Verteporfin of subfoveal choroidal neovascularization in age- related macular degeneration: Study design and baseline characteristics in the VIP randomized clinical trial. Invest Ophthalmol Vis Sci 40 (4) (Suppl): 1703 1999.

9.2.20. Monés JM. Reunión de casos clínicos: Retina y Vítreo. Andorra, January 2000.

9.2.21. Monés JM. Principle Aspects of Clinical Trials of Photodynamic Therapy with Verteporfin (VisudyneTM): Phase I and II, and phase III (TAP and VIP Study) in the treatment of CNV secondary to AMD y Pathologic Myopia. International Symposium Ocular Pharmacology. and Pharmaceutics. Lisbon, February 12, 2000.

9.2.22. Monés JM. One-year Angiographic Outcomes and Safety Following Photodynamic Therapy with Verteporfin (Visudyne) for subfoveal choroidal neovascularization in AMD – Results of Two

C. Vitae Jordi Monés 38

Randomized Phase III Clinical Trials (TAP Investigation) International Symposium Ocular Pharmacology. and Pharmaceutics. Lisbon, February 12, 2000.

9.2.23. Monés JM. One-year Angiographic Outcomes and Safety Following Photodynamic Therapy with Verteporfin (Visudyne) for subfoveal choroidal neovascularization in AMD – Results of Two Randomized Phase III Clinical Trials (TAP Investigation) VI Mediterranean Ophthalmological Society Congress and VI Michaelson Symposium on Ocular Circulation and Neovascualrization. Jerusalem, Israel, May 24, 2000.

9.2.24. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia Using Verteporfin (Visudynetm); One-year Results – VIP Report #1. The Retina Society 33RD Annual Meeting. Coral Gables, FLA, USA, November 30 - December 3, 2000.

9.2.25. Polypoidal Choroidal Vasculopathy in recurrent CNV after PDT. The Retina Society 34rd Annual Meeting. Chiacago, USA October 14- 17 2001 (It was going to be presented, Meeting Cancelled due to September 11th 2001)

9.2.26. Safety of multiple consecutive areas of light application during treatment of CNV with PDT. Reinaldo Castillo, Javier Moreno,Gilberto Rosales, Fernanda Vaz, Jordi Monés. Euretina Meeting. Barcelona, May, 2002.

9.2.27. Photodynamic therapy in myopic CNV. Euretina Meeting. Barcelona, May, 2002.

9.2.28. A New Automated Quantified Macular Metamorphopsia Measurement in CNV treated with PDT. 25th ANNUAL MACULA SOCIETY MEETING. Barcelona, June, 2002

C. Vitae Jordi Monés 39

9.2.29. Analysis of safety data of three randomized Trials of Verteporfin therapy in the treatment of neovascular AMD XXIIIrd Congress of the Club Jules Gonin in Montreux, Switzerland, 31 August - 4 Sep, 2002.

(PRESENTATIONS and LECTURES are presented together from this point in the section 11.2)

10. TEACHING ACTIVITIES and INVITED LECTURES:

10.1. Organization of Scientific Courses:

10.1.1. Co-organization Curso " NUEVAS TÉCNICAS DE EXAMEN DEL FONDO DE OJO: LA OFTALMOSCOPÍA CON LÁSER DE BARRIDO (SLO)". Directores del Curso: Jordi Monés, Borja Corcóstegui. Centro Retina Vitreo, Barcelona, October 23, 1993.

10.1.2. Fundator del “Club Angiográfico Fluoresceina – Indocianina, Club FLIN”

10.1.3. Organization I Reunión Club Angiográfico FLIN. October 1995, Barcelona.

10.1.4. Organization II Reunión Club Angiográfico FLIN. September 1996, Madrid.

10.1.5. Organization III Reunión Club Angiográfico FLIN. September 1997, Granada.

10.1.6. Co-organization Curso: Luxación posterior de núcleos (Facoemulsificación ) y de LIO. Soluciones quirúrgicas. Implantes secundarios. Directores: JR Soler Tomás, J Monés Carilla. LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Granada, September 24-28, 1997.

10.1.7. Organization n IV Reunión Club Angiográfico FLIN. Alicante, September 1988.

10.1.8. Co-organization I Reunión Grupo de Terapia Fotodinámica.

C. Vitae Jordi Monés 40

Venecia July 1999.

10.1.9. Organization V Reunión Club Angiográfico FLIN. Málaga, September 1999.

10.1.10. Co-organization Curso Angiografía con Verde de Indocianina. LXXV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Málaga, September 22, 1999.

10.1.11. Co-organization Curso Casos . LXXV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Málaga, September 22, 1999.

10.1.12. Co-organization II Reunión Grupo de Terapia Fotodinámica.Deià, January, 2000.

10.1.13. Co-organization III Reunión Grupo de Terapia Fotodinámica. Valladolid, June 2000.

10.1.14. Organization VI Reunión Club Angiográfico FLIN. Madrid October 2000.

10.1.15. Chairperson Symposia: Visudyne: La Terapia Fotodinámica en Oftalmología. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, 11-15 October, 2000.

10.1.16. Coordinator: Round Table “Tratamiento con Láser, Terapeútica Fotodinámica y Ayudas Visuales en DMAE. XI CONGRESO DE LA SOCIEDAD ARAGONESA DE OFTALMOLOGÍA. Zaragoza, 10-11 November , 2000.

10.1.17. Organization and Coordination of an Interactive Course (700 people) “Alternativas Terapeúticas de la Neovascularización Coroidea: Discusión de Casos Clínicos” V CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO. Madrid, 2- 3 -March, 2001

10.1.18. Current Trials on Visudyne: 4th Int. Symp. on Ocular

C. Vitae Jordi Monés 41

Pharmacology and Pharmaceutics. Seville, March, 2002.

10.1.19. Course: Clinical Cases. II European Congress of PDT. Barcelona, September, 2002.

10.1.20. Mesa redonda: "Avances en el tratamiento de la DMAE". Moderador: Jordi Monés. Congreso Sociedad Española de Retina y Vítreo. Santiago de Compostela, March, 2004.

10.1.21. Meeting New Horizons in AMD. Barcelona, March, 2005.

10.1.22. Ponencia Oficial 81 Congreso Sociedad Española de Oftalmología, “La degeneración macular asociada a la edad”. Zaragoza, Sept, 2005.

10.1.23. Actualización en DMAE. Directores: Jordi Monés i Carilla, Francisco Gómez-Ulla de Irazazábal Nivel: Avanzado. 83 Congreso de la Sociedad Española de Oftalmologia. Las Palmas de Gran Canaria, Sept 26-29 , 2007.

10.1.24. Jordi Monés, Bayer Educational Slide Development/Speaker Training. Vancouver, January 21-22, 2012.

10.2. Invited Lectures and invited participation in Courses:

10.2.1. Lecture: "Exploración Angiogràfica de la Coroides". I CURSO DE PATOLOGÍA E INVESTIGACIÓN VÍTREAS. Valladolid, May 23-25, 1991.

10.2.2. Lecture: "Angiografía con indocianina verde mediante SLO en la DMAE". CURS DE DOCTORAT 1993 - 94, UNIVERSITAT AUTÒNOMA DE BARCELONA, HOSPITAL DE LA VALL D'HEBRON. Barcelona, April 1993.

10.2.3. Discussion Poster Presentation: LXIX CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Santiago de

C. Vitae Jordi Monés 42

Compostela, October 3, 1993.

10.2.4. Lecture: "AFG del Futuro". CURSO TEÓRICO-PRÁCTICO DE LASERTERAPIA BÁSICA ARGON-YAG EN OFTALMOLOGÍA. Elx, October 22, 1993.

10.2.5. Lecture: "Principios de la angiografía con indocianina verde". Curso " NUEVAS TÉCNICAS DE EXAMEN DEL FONDO DE OJO: LA OFTALMOSCOPÍA CON LÁSER DE BARRIDO (SLO)". Centro Retina Vitreo. Barcelona, October 23, 1993.

10.2.6. Lecture: "Angiografía con indocianina verde mediante SLO en la DMAE". Curso " NUEVAS TÉCNICAS DE EXAMEN DEL FONDO DE OJO: LA OFTALMOSCOPÍA CON LÁSER DE BARRIDO (SLO)". Centro Retina Vitreo. Barcelona, October 23, 1993.

10.2.7. Lecture: "Oftalmoscopia con Láser de Barrido (SLO)." "CURSO DE ACTUALIZACIÓN EN OFTALMOLOGÍA", HOSPITAL PUERTA DE HIERRO. Madrid, December 11, 1993.

10.2.8. Lecture: "Detección de neovasos subretinianos utilizando verde de indocianina con el SLO". "CURSO DE AVANCES EN TÉCNICAS QUIRÚRGICAS DE MICROCIRUGÍA OCULAR". Universitat Autònoma de Barcelona. Barcelona, March 18, 1994.

10.2.9. Lecture: "Angiografía con indocianina verde - SLO en la degeneración macular asociada a la edad". "SEMINARIO DEL MES DE JUNIO" HOSPITAL UNIVERSITARIO, UNIVERSIDAD DE VALLADOLID. Valladolid, June 25, 1994.

10.2.10. Round Table: "MESA REDONDA: Nuevos Métodos de Exploración Retiniana". Participantes: Bertoja E, Marín F, Monés J, Scheider A. Moderador: Gómez-Ulla F. LXX CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Tenerife, September

C. Vitae Jordi Monés 43

30 - October 4, 1994.

10.2.11. Lecture: "Aplicaciones del Oftalmoscopio de Làser de Barrido para las patologías de la Mácula". "JORNADAS CIENTÍFICAS 50 ANIVERSARIO DE LA FUNDACIÓN DE LA CLÍNICA QUIRÓN". Barcelona, November 12, 1994.

10.2.12. Lecture: "Exploración de la circulación coroidea mediante Videoangiografía con Verde de Indocianina - SLO" "CURSO DE ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago de Compostela, November 17-19, 1994.

10.2.13. Lecture: "Videoangiografía - SLO en las enfermedades inflamatorias de la coroides y epitelio pigmentario". "CURSO DE ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago de Compostela, November 17-19, 1994

10.2.14. Lecture: "Clasificación de los patrones angiográficos con AVI - SLO en las membranas neovasculares de la DMAE”. "CURSO DE ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago de Compostela, November 17-19, 1994.

10.2.15. Lecture: "Circulación coroidea de las formas exudativas de la DMAE mediante VAGF-SLO." "CURSO DE ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago de Compostela, November 17-19, 1994.

10.2.16. Lecture: "Oftalmoscopía làser de barrido (SLO) en el diagnóstico y tratamiento de las patologías maculares". "SIMPOSIUM MONOGRÁFICO SOBRE LA MÁCULA: NUEVAS TÉCNICAS DIAGNÓSTICAS Y TERAPEÚTICAS". Valencia, January 14, 1995.

10.2.17. Round Table: "MESA REDONDA: Angiografía con verde de Indocianina en la práctica oftalmológica". Participantes: Flower R, Guyer D, Marín F, Monés J, Ruiz-Moreno JM. Moderador: Gómez-Ulla

C. Vitae Jordi Monés 44

F. " II CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VÍTREO". Madrid, February 24 - 25, 1995.

10.2.18. Lecture: " Angiografia amb indocianina verda: Avantatges i aplicacions". "Departament d'Oftalmologia Clínica L'Aliança". Barcelona, March 31, 1995.

10.2.19. Lecture: “Degeneració macular senil lligada a l’edat. Aspectes clínics. Angiografies. SLO. “II JORNADA OFTALMOLOGICA DE TARRAGONA: Lesions Maculars i Baixa visió”. Tortosa, May 4, 1996.

10.2.20. Lecture: "Utilidad del Scanning Laser Ophthalmoscope en el diagnóstico diferencial de los tumores intraoculares". "CURSO DE AVANCES EN EL TRATAMIENTO MÉDICO Y QUIRÚRGICO DE LOS TUMORES INTRAOCULARES". Institut de Microcirurgia Ocular de Barcelona. Barcelona, June 2-3, 1995.

10.2.21. Lecture: "Angiografía con indocianina verde. En: Uveitis: Técnicas diagnósticas y de tratamiento". "IV CURSO DE IMMUNOLOGIA OCULAR. MONOGRÁFICO: UVEITIS." IOBA, Universidad de Valladolid. Sevilla, June 21-23, 1995.

10.2.22. Lecture: Scanning laser, angiografía con verde de indocianina y microperimetría”. “TECNICAS DIAGNOSTICAS EN OFTALMOLOGIA”. Pamplona, January 19-20, 1996.

10.2.23. Lecture: “Aplicaciones de la AVI en el diagnóstico y tratamiento de las membranas neovasculares subretinianas” “FORMACION MEDICA CONTINUADA DEL ILMO. COL. MEDICOS ALICANTE. ACTUALIZACION EN ANGIOGRAFIA”. Alicante, February 3, 1996.

10.2.24. Course: “ Curso avanzado sobre angiografía con indocianina verde” “1º CURSO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO”. Valladolid, February 24, 1996.

C. Vitae Jordi Monés 45

10.2.25. Round Table: “Retina Médica”. VII CONGRESO DE LA SOCIEDAD ARAGONESA DE OFTALMOLOGIA. Zaragoza, November 15-16, 1996.

10.2.26. Lecture: “Protocolo de la Terapia Fotodinámica” Mesa Redonda MACULA. III CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO. Madrid, February 21-22, 1997.

10.2.27. Lecture: “Verde de indocianina en las enfermedades inflamatorias intraoculares”. “AVANCES EN EL DIAGNOSTICO Y TRATAMIENTO DE LA INFLAMACION OCULAR”. Barcelona, May 23, 1997.

10.2.28. Round Table: “Degeneración macular asociada a la edad. Terapia fotodinámica en las formas exudativas de la DMAE”. LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Granada, September 24-28, 1997.

10.2.29. Discussion Poster Presentation LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Granada, September 25, 1997.

10.2.30. Course: “LIO en ausencia de cápsula” LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Granada, September 25, 1997.

10.2.31. Course: La angiografía con indocianina en la préactica clínica. LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Granada, September 25, 1997.

10.2.32. Lecture: “Hallazgos angiográficos mediante verde de indocianina en las enfermedades inflamatorias coroideas”. CURSO “LA MÁCULA: DIAGNÓSTICO Y TRATAMIENTO QUIRÚRGICO”. Hospital Clínic i Universitari. Valencia, January 16-17, 1998.

C. Vitae Jordi Monés 46

10.2.33. Lecture: “Terapia fotodinámica mediante verteporfina para el tratamiento de las formas exudativas subfoveales de la degeneración macular asociada a la edad”. CURSO “LA MÁCULA: DIAGNÓSTICO Y TRATAMIENTO QUIRÚRGICO”. Hospital Clínic i Universitari. Valencia, January 16-17, 1998.

10.2.34. Lecture: “Terapia fotodinámica mediante verteporfina para el tratammiento de las formas exudativas subfoveales de la degeneración macular asociada a la edad”. SEMINARIO. DEPARTAMENTO DE OFTALMOLOGIA, FACULTAD DE MEDICINA UNIVERSIDAD DE VALLADOLID. Valladolid, January 24, 1998.

10.2.35. Clinical Cases: Presentación interactiva de casos clínicos: II CURSO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VÍTREO. Sevilla, February 28, 1998.

10.2.36. Lecture: “Terapia Fotodinámica en la Neovascularización Coroidea”. CURSO DE POSTGRADO RETINA MÉDICA Y QUIRÚRGICA. Casos Especiales. Institut Universitari Barraquer. Barcelona, March 28, 1998.

10.2.37. Lecture: “Terapia Fotodinámica en la Neovascularización Coroidea”. NUEVAS PERSPECTIVAS EN LA DEGENERACIÓN MACULAR ASOCIADA A LA EDAD. Instituto Clínico Quirúrgico de Oftalmología. Bilbao, April 25, 1998.

10.2.38. Round Table: “Estado Actual de la Patología Macular”. XXX CONGRESO DE LA SOCIEDAD OFTALMOLÓGICA DE ANDALUCIA Y EXTREMADURA. Marbella, June 26-28, 1998.

10.2.39. Course: “Alternativas terapeúticas de la DMAE”. 74 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA. Alicante, Sept 30 -October 4, 1998.

10.2.40. Course: “ Angiografía con verde de indocianina”. 74

C. Vitae Jordi Monés 47

CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA. Alicante, Sept 30 - October 4, 1998.

10.2.41. Lecture: “Avances en el diagnóstico y tratamiento no quirúrgico de las enfermedades de la mácula.” I CURSO DE ACTUALIZACIÓN EN EL DIAGNOSTICO Y TRATAMIENTO DE LAS ENFERMEDADES DE LA MACULA. Sociedad Canaria de Oftalmología. Las Palmas, November 27-28, 1998.

10.2.42. Lecture: Terapia Fotodinámica: Nuevas Técnicas Quirúrgicas e Instrumentos. IV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VÍTREO. Madrid, February 19-20, 1999.

10.2.43. Lecture: “Nou tractament de la degeneració macular. Terapia Fotodinámica” Hospital de la Creu Roja. Barcelona, March 10, 1999.

10.2.44. Lecture: Oclusiones coroideas asociadas al tratamiento de la neovascularización subretiniana. III Curso Internacional de Retina Médica y Diabetes Ocular. Santiago de Compostela, April 23-24, 1999.

10.2.45. Lecture: Terapia Fotodinámica en la DMAE. Resultados preliminares. III Curso Internacional de Retina Médica y Diabetes Ocular. Santiago de Compostela, April 23-24, 1999.

10.2.46. Training Course: Introducción a la Terapia Fotodinámica y Resultados Ensayo Clínico Fase I y Fase III TFD. Curso – I Reunión Grupo de Terapia Fotodinámica. Venecia, July 1999.

10.2.47. Training Course Descripción Ensayo Clínico Fase III TFD. Curso – I Reunión Grupo de Terapia Fotodinámica. Venecia, July 1999.

10.2.48. Training Course Resultados Ensayo Clínico Fase III TFD. Curso – I Reunión Grupo de Terapia Fotodinámica. Venecia, July 1999.

10.2.49. Training Course Presentación de casos clínicos. Revisión criterios de inclusión TFD en uso compasivo. Curso- I Reunión Grupo de Terapia Fotodinámica. Venecia, July, 1999.

C. Vitae Jordi Monés 48

10.2.50. Training Course: Fundamentals of Photdynamic Therapy (TFD). Training course VIT (Verteporfin Italy Trial). Sardinia, September, 1999.

10.2.51. Training Course: Phase I-III of Photodynamic Therapy with Verteporfin. Training course VIT (Verteporfin Italy Trial). Sardinia, September, 1999.

10.2.52. Training Course: Case presentation. Phase I and phase II of Photodynamic Therapy with Verteporfin. Training course VIT (Verteporfin Italy Trial). Sardinia, September, 1999.

10.2.53. Course: Angiografía con Verde de Indocianina. LXXV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Málaga, September 22, 1999.

10.2.54. Course: Casos clínicos . LXXV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Málaga, September 22, 1999.

10.2.55. Discussion Poster Presentation: LXXV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Málaga, September 24, 1999.

10.2.56. Round Table. Terapia Fotodinámica con Verteporfin. Symposium Degeneración Macular Asociada a la Edad. LXXV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Málaga, September 24, 1999.

10.2.57. Visudyne Therapy. CibaVision in-booth theather. American Academy of Ophthalmology. Orlando, USA. October 25, 1999.

10.2.58. Round Table: Degeneració macular associada a l’edat: possibilitats actuals de tractament. Terapia Fotodinámica. Aplicació actual. 30 Congrés de la Societat Catalana d’Oftalmologia. Barcelona, November 25-27, 1999.

C. Vitae Jordi Monés 49

10.2.59. Lecture: Terapia Fotodinámica con Verteporfin. XLII Congresso de la Sociedade Portuguesa de Oftalmologia. Lisboa, December 1-4, 1999.

10.2.60. Lecture: Principles of Photodynamic Therapy. “Photodynamic Therapy Leaders Symposium”. Vienna, December 11, 1999.

10.2.61. Lecture: Estado actual del uso compasivo de la Terapia Fotodinámica para el tratamiento de la neovascularización coroidea secundaria a DMAE. Mallorca, January, 2000

10.2.62. Lecture: Ull vermell i Glaucoma. XII Curs de Formació Continuada. Actualitzacions diagnòstiques i Terapeútiques. Hospital de Mataró . Barcelona, February 24, 2000.

10.2.63. Lecture: Estat actual de la Terapia Fotodinámica en Degeneració Macular Asociada a la Edad. XII Curs de Formació Continuada. Actualitzacions diagnòstiques i Terapeútiques. Hospital de Mataró. Barcelona, February 24, 2000

10.2.64. Course: DECISIONES TERAPEÚTICAS siguiendo CRITERIOS ANGIOGRÁFICOS. Curso Angiografía y su Implicación Terapeútica en DMAE. Curso de la Sociedad Española de Retina Vítreo. Bilbao, February 26, 2000.

10.2.65. Lecture: Estado actual Terapia Fotodinámica. Sesión Degeneración Macular Asociada a la Edad. Curso de la Sociedad Española de Retina Vítreo. Bilbao, February 26, 2000.

10.2.66. Lecture: One-year results of TAP Study of Photodynamic Therapy with Verteporfin. Vitreoretinal Interface Course. Rome, March 31, 2000.

10.2.67. Lecture: Estado Actual de la Terapia Fotodinámica. Symposium

C. Vitae Jordi Monés 50

de Terapia Fotodinámica con Verteporfin. Buenos Aires, Argentina. May 11, 2000.

10.2.68. Lecture: Estado Actual de la Terapia Fotodinámica. Curso de Perfeccionamiento para Oftalmólogos. Sociedad Chilena de Oftalmología. Santiago de Chile, Chile. May 12, 2000.

10.2.69. Lecture: Decisiones Terapeúticas siguiendo criterios angiográficos en DMAE. Curso de Perfeccionamiento para Oftalmólogos. Sociedad Chilena de Oftalmología. Santiago de Chile, Chile. May 12, 2000.

10.2.70. Breakfast with Experts: Terapia Fotodinámica. Curso de Perfeccionamiento para Oftalmólogos. Sociedad Chilena de Oftalmología. Santiago de Chile, Chile. May 12, 2000.

10.2.71. Resultados Uso Compasivo Terapia Fotodinámica en DMAE. Curso Nuevos Avances en el Diagnóstico y Tratamiento quirúrgico en Oftalmología. Servicio Oftalmología Hospital Vall d’Hebrón. Barcelona, May 19- 20, 2000.

10.2.72. Lecture: Protoporfirinas en la DMAE. Actualización en Degeneraciones y Distrofias Retinianas. IOBA. Valladolid, June-3, 2000.

10.2.73. Lecture: Terapia Fotodinámica en miopía. Miopía 2000. Asociación Oftalmológica del Norte. Vitoria, Spain. June 9, 2000.

10.2.74. Lecture: Fundamentals of Photodynamic Therapy. Creteil Course on PDT. Cannes, France. June 10, 2000.

10.2.75. Lecture: Photodynamic Therapy in Myopia: VIP Trial. UK Visudyne Symposium. Geneve, September 30, 2000.

10.2.76. Compassionate use in Barcelona of Photodymanic Therapy: 1 year results. UK Visudyne Symposium. Geneve, September 30, 2000.

C. Vitae Jordi Monés 51

10.2.77. TAP Study. 2-year angiographic results. Symposia: Visudyne: La Terapia Fotodinámica en Oftalmología. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, 11-15 October, 2000.

10.2.78. Terapia Fotodinámica: 1 año de resultados en Fase de Uso Compasivo en Barcelona. Symposium Visudyne: La Terapia Fotodinámica en Oftalmología. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, October 14, 2000.

10.2.79. Decisiones Terapeúticas para la DMAE sobre criterios angiográficos. Symposium en Degneración Macular Asociada a la Edad. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, October 15, 2000.

10.2.80. Desayuno con expertos. Degeneración Macular Asociada a la edad. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, October 14, 2000.

10.2.81. Terapia Fotodinámica Estudio TAP: Resultados 2 años. Reunión Satélite AMERICAN ACADEMY OF OPHTHALMOLOGY MEETING 2000, Symposium Visudyne Iberoamérica. Dallas, October 23, 2000.

10.2.82. Instructor Skill transfer Program: Photodynamic Therapy: Current treatment guidelines for choroidal neovascularization. Course HO-601. AMERICAN ACADEMY OF OPHTHALMOLOGY MEETING. Dallas, October 25, 2000.

10.2.83. Terapéutica Fotodinámica. Experiencia personal y Estudio multicéntrico. XI CONGRESO DE LA SOCIEDAD ARAGONESA DE

C. Vitae Jordi Monés 52

OFTALMOLOGÍA. Zaragoza, November 10-11, 2000.

10.2.84. Mesa Redonda “Terapéuticas Acctuales en la Degeneración de Mácula asociadas a la Edad” REUNION ANUAL DE LA ASOCIACIÓN OFTALMOLÓGICA DEL NORTE. Bilbao, November 18, 2000.

10.2.85. Terapia Fotodinàmica amb Verteporfino en DMAE. Estudi TAP: Resultats de 2 anys. Satellite Symposium 31 CONGRÉS DE LA SOCIETAT CATALANA D’OFTALMOLOGIA”. Barcelona, November 23-24, 2000.

10.2.86. Experiencia en Terapia Fotodinámica en Oftalmología. X CONGRESO DE LASER EN MEDICINA Y CIRUGÍA. México DF, México. November 28 , 2000.

10.2.87. Estado Actual de Ensayos Clínicos en la Neovascularización Coroidea SESION CLÍNICA INSTITUT MICROCIRURGIA OCULAR DE BARCELONA. Barcelona, February, 2001.

10.2.88. Estado Actual de Ensayos Clínicos en la Neovascularización Coroidea. V CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO. Madrid, March 2- 3, 2001

10.2.89. Lecture: The TAP Study. NEW ASPECTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION. Rome, March 10, 2001.

10.2.90. Terapia Fotodinámica en Miopía y Degeneración Macular Asociada a la Edad ( Estudio VIP, resultados a 24 meses ). III CURSO INTERNACIONAL “LO ACTUALMENTE POSIBLE EN ENFERMEDADES VITREORRETINIANAS” México DF, México. 22-24 de Marzo 2001.

10.2.91. Ensayo Clínico de la Degeneración Macular Asociada a la Edad

C. Vitae Jordi Monés 53

(Estudio TAP) Resultados a 36 meses ). III CURSO INTERNACIONAL “LO ACTUALMENTE POSIBLE EN ENFERMEDADES VITREORRETINIANAS” México DF, México. March 22-24, 2001.

10.2.92. Management of Visudyne Therapy: Treatment and follow-up procedures. Course Visudyne therapy for Neovascular Disorders of the Macula – Introduction to Visudyne Therapy. XIII Congress of The European Society of Ophthalmology. Istanbul, June -7, 2001.

10.2.93. Visudyne Therapy in Pathologic Myopia: 24-month Update from VIP Study. Symposia Visudyne in Clinical Practice: Trial Updates and Recommended Patient Management. XIII Congress of The European Society of Ophthalmology. Istanbul, June -7, 2001.

10.2.94. Control del Paciente. Indicación de los retratamientos. Simposium sobre Fototerapia Dinámica. GLADAOF Meeting. Buenos Aires, July 21, 2001.

10.2.95. Paper: Visudyne Therapy in Patients with AMD: Experience from Trials and Clinical Practice. 77 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Barcelona, October, 2001.

10.2.96. Lecture: Current and Future Treatments in AMD. Challenges In PDT For Choroidal Neovascularisation, Liverpool Medical Institution. Liverpool, October 16, 2001.

10.2.97. Lecture: Terapia Fotodinàmica en DMAE: Patología de la Mácula, Alicante, October 19,2001..

10.2.98. Lecture: Current and Future Treatments in AMD. Curso Actualizaçáo Oftalmológica. Lisboa, October 27, 2001.

10.2.99. Clinical Session.Casos Clínicos: Retratamientos TFD en NVC – Miopía.Monitorización Metamorfopsia. I.M.O. Barcelona, January 29, 2002

10.2.100. Polypoidal Choroidal Vasculopathy in recurrent CNV after PDT

C. Vitae Jordi Monés 54

Clinical Session. Reunió Hivern Retina de Barcelona. Baqueira, February, 2002.

10.2.101. Anti-VEGF in exudative AMD 4th Int. Symp. On Ocular Pharmacology and Pharmaceutics. Seville, March, 2002.

10.2.102. Decision making in PDT retreatments. Monitoring metamorphopsia. 4th Int. Symp. On Ocular Pharmacology and Pharmaceutics,Seville, March 2002

10.2.103. Current trials on Visudyne. 4th Int. Symp. On Ocular Pharmacology and Pharmaceutics. Seville, March, 2002.

10.2.104. Discussion Paper: Lluis Arias, TFD en C.S.U. Bellvitge: Resultados en DMAE y MP. VI CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO. San Sebastián, March, 2002.

10.2.105. Current and FutureTreatments in AMD. Padova, April 4, 2002.

10.2.106. Principles of Photodynamic Therapy. TÜRK OFTALMOLOJI DERNEGI. Ankara, April, 2002.

10.2.107. Visudyne Therapy in Patients with AMD:Experience from Trials and Clinical Practice. TÜRK OFTALMOLOJI DERNEGI. Ankara, April, 2002.

10.2.108. Photodynamic Therapy with Verteporfin in AMD. Experience from Trials and Clinical Practice. TÜRK OFTALMOLOJI DERNEGI. Ankara, April, 2002.

10.2.109. Treatment Response — Beyond Visual Acuity. International Congress in Opthalmlogy. Sidney, Australia. April, 2002.

10.2.110. Terapia Fotodinámica. Retratamientos. Actualización en el diagnóstico y tratamientos de complejos neovasculares subretinianos. Madrid, May 11, 2002.

C. Vitae Jordi Monés 55

10.2.111. Visudyne Therapy in Patients with AMD:Experience from Trials and Clinical Practice. Actualización en el diagnóstico y tratamientos de complejos neovasculares subretinianos. Madrid, May 11, 2002.

10.2.112. Current Trials on Visudyne: Rationale for VER and VIM Study. Actualización en el diagnóstico y tratamientos de complejos neovasculares subretinianos. Madrid, May 11, 2002.

10.2.113. Practical algorithms on PDT retreatment in AMD and myopia. G.I.V.R.E. Course. Parma, May, 2002.

10.2.114. Course: Clinical Cases. II European Congress of PDT. Barcelona, September, 2002.

10.2.115. Clinical Session: Tratamientos vasos nutricios en Neovascularización coroidea. I.M.O. Barcelona, December 10, 2002.

10.2.116. Tratamiento de la neovascularización coroidea: Actividad de alto riesgo? Curso Actualización DMAE. Sevilla, January 25, 2003.

10.2.117. Tratamiento de la neovascularización coroidea: Actividad de alto riesgo? VII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO. Madrid, February 27, 2003.

10.2.118. Clinical Session: The Anecortave Acetate for Exudative AMD: Clinical Outcomes and Status of Clinical Studies. I.M.O. Barcelona, May, 2003.

10.2.119. Lecture: The Anecortave Acetate for Exudative AMD: Clinical Outcomes and Status of Clinical Studies. 14th Congress of The European Society of Ophthalmology. Madrid, June, 2003

10.2.120. Lecture: Is Lesion Size as Important as Lesion Composition? 14th Congress of The European Society of Ophthalmology. Madrid, June 2003

C. Vitae Jordi Monés 56

10.2.121. Lecture: The Anecortave Acetate for Exudative AMD: Clinical Outcomes and Status of Clinical Studies. Firenze, September 4, 2003.

10.2.122. Lecture: Preferential Hyperacuity Perimetry (PHP): A new way for monitoring CNV progression. VI INTERNATIONAL CONGRESS:Myopia and Related Diseases: A clinical and therapeutic approach. Rome. September, 2003

10.2.123. Lecture: Implications of contrast sensitivity preservation in AMD patients treated with Visudyne therapy. III European Congress on PDT in AMD Management. Cannes, October 3-4, 2003.

10.2.124. PDT using delayed light application in occult lesions: Results from VALIO. III European Congress on PDT in AMD Management. Cannes, October 3-4, 2003.

10.2.125. Clinical Session: Translocación Macular asociado a Terapia Fotodinámica en NVC 2ria a Miopia Patológica. I.M.O. Barcelona, October 14, 2003.

10.2.126. Course: Translocación Macular asociado a Terapia Fotodinámica en NVC 2ria a Miopia Patológica. 79 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLCGÍA. Valencia, October 2003.

10.2.127. Lecture: Is Lesion Size as Important as Lesion Composition? V Reunión Club Visudyne. Las Vegas USA, November, 2003.

10.2.128. Management of AMD, Training course for the Alcon company executives. Barcelona, December, 2003

10.2.129. Current management in AMD, QLTI Analyst and Investor Meeting. New York, December, 2003.

C. Vitae Jordi Monés 57

10.2.130. Tratamiento NVC en la Retinopatía Diabética. Curso Oftalmodiabetes, Hospital de l’Esperança. Barcelona, February, 2004

10.2.131. Preferential Hyperacuity Perimetry (PHP) for monitoring myopic CNV treated with PDT. 2004 Annual Meeting Macula Society. Las Vegas, 2004.

10.2.132. Mesa redonda: "Avances en el tratamiento de la DMAE ".Moderador: Jordi Monés. Congreso Sociedad Española de Retina y Vítreo. Santiago de Compostela, March, 2004.

10.2.133. Terapia Fotodinámica y Corticoides. Congreso Sociedad Española de Retina y Vítreo. Santiago de Compostela, March, 2004.

10.2.134. Tratamiento antiangiogénico en DMAE. Congreso Sociedad Española de Retina y Vítreo. Santiago de Compostela, March, 2004.

10.2.135. PDT New drugs. Panel discussion. ISOPT Meeting, Montecarlo, March, 2004.

10.2.136. Refining Management of CNV due to AMD − Maximising Patient Benefit through Prompt and Appropriate Treatment. ISOPT Meeting, Montecarlo, March, 2004.

10.2.137. Tratamiento combinado:TFD + triamcinolona IVIT en NVC. Sesión Clínica IMO, Barcelona, March, 2004.

10.2.138. Curso Angiográfico Hospital de Sant Pau. Barcelona, April, 2004

10.2.139. Terapia Antiangiogénica. Curso Macula. Institut Oftalmologia

C. Vitae Jordi Monés 58

Barraquer, June, 2004.

10.2.140. Terapia Antiangiogénica. Curso Instituto Fernández-Vega. Oviedo, June 2004.

10.2.141. Terapia combinada, PDT y triamcinolona. Reunión de trabajo Club Visudyne. Sitges, September 2004.

10.2.142. Chair: Jordi M. Mones, MD,Section II: Photodynamic Therapy and Corticosteroids for AMD. Subspecialty day Retina, Annual Meeting of the American Academy of Ophthalmology. New Orleans, USA. October 2004.

10.2.143. Pfizer Macugen Worldwide Advisory Board. New Orleans, USA. October 2004.

10.2.144. Preferential Hyperacuity Perimetry for monitoring CNV. Couse (E. Midena) at the Annual Meeting of the American Academy of Ophthalmology. New Orleans, USA October 2004.

10.2.145. Efficacy of Macugen. Reunión Mexican Advisory Board. Cuernavaca, México. October, 2004.

10.2.146. Safety of Macugen. Efficacy of Macugen. Reunión Mexican Advisory Board. Cuernavaca, México. October, 2004.

10.2.147. Meeting of the European Group for the guidelines of treatment of AMD. Paris, November, 2004.

10.2.148. Clinical cases presentation. Soc. Lombarda oftalmologia. Milan December, 2005.

C. Vitae Jordi Monés 59

10.2.149. Curso Formación Degeneración Macular asociada a a la edad, Pfizer. Madrid, December, 2004

10.2.150. Sesión clínica IMO. Fármacos intravítreos. IMO. Barcelona, January, 2005.

10.2.151. Casos clínicos. Andorra, February 2005.

10.2.152. Tratamiento Combinado en NVC: Terapia Fotodinámica y Triamcinolona transeptal. Reunión Sociedad Española de Retina y Vítreo, Madrid, February, 2005.

10.2.153. Curso satélite para oftalmólogos “Perimetría de Hiperagudeza Preferencial”. Reunión Sociedad Española de Retina y Vítreo. Madrid, February, 2005.

10.2.154. Curso satélite para ópticos y periodistas. “Perimetría de Hiperagudeza Preferencial”. Reunión Sociedad Española de Retina y Vítreo. Madrid February, 2005.

10.2.155. Clinical case presentation session. Meeting New Horizons in AMD. Barcelona, March, 2005.

10.2.156. Anti-VEGF therapy: clinical efficacy and safety of Macugen New Horizons in AMD. Barcelona, March, 2005.

10.2.157. Esquema diagnóstico y tratamiento en DMAE. Reunión Panamerican Academy of Ophthalmology. Santiago de Chile, March, 2005.

C. Vitae Jordi Monés 60

10.2.158. Update in Macugen, Reunión Panamerican Academy of Ophthalmology. Santiago de Chile, March, 2005.

10.2.159. Macugen therapy. Sessió clínica Hospital de la Vall d’Hebró. April 2005

10.2.160. Update in Macugen. Euretina Meeting. Barcelona, May, 2005.

10.2.161. Limitations of intravitreal triamcinole as adjuntive therapy with PDT. Meeting “Retina in Progress” Prof. A Pecce. Milan, Italy, June, 2005.

10.2.162. Terapia antiangiogénica. Sesión clínica Hospital de l’Esperança. Barcelona, June, 2005.

10.2.163. Limitaciones de la triamcinolona intravítrea. Curso de la APEC, Ciudad de México. México, September 2005.

10.2.164. Perimetría de hiperagudeza preferencial. Curso de la APEC, Ciudad de México. México, September, 2005

10.2.165. Esquema diagnóstico y terapeútico de la DMAE. Curso de la APEC, Ciudad de México. México, September, 2005.

10.2.166. Tratamiento con pegaptanib sódico, Macugen, en DMAE. Curso de la APEC, Ciudad de México. México, September, 2005.

10.2.167. Main Lecture of the 81 Meeting of the Spanish Society of Ophthalmology: Degeneración Macular Asociada a la Edad”. 81 reunión de la Soc. Esp. Oftalmología. Zaragoza, September, 2005.

C. Vitae Jordi Monés 61

10.2.168. Lo mejor de la reunión de ARVO, 81 reunión de la Soc. Esp. Oftalmología, Zaragoza, September, 2005

10.2.169. Update in Macugen. 81 reunión de la Soc. Esp. Oftalmología. Zaragoza, September, 2005.

10.2.170. Macugen and Neovascular AMD. VISION Trials. 2 year data. EVER 2005. European Association for Vision and Eye Research. Vilamoura, Portugal October 5-8, 2005.

10.2.171. Que cal retenir dels Assaigs Clínics de DMAE. Societat Catalana d’Oftalmologia. Catalunya, November 24-25, 2005

10.2.172. Macugen for CNV/ AMD. Ocular Pharmacology and Therapeutics (ISOPT). Berlin, March 30-April 2, 2006.

10.2.173. Macugen for DME Ocular Pharmacology and Therapeutics (ISOPT). Berlin, March 30-April 2, 2006.

10.2.174. Co-chair session Macular edema. Ocular Pharmacology and Therapeutics (ISOPT). Berlin, March 30-April 2, 2006.

10.2.175. Macugen World Wide Advisory Board Meeting. Fort Lauderdale, May 5-6, 2006.

10.2.176. J. Mones, J. Lotery, J. Pauleikhoff, G. Soubrane, A. Cruess, G. Zlateva. Humanistic burden and health resource utilitsation among neovascular age-related macular degeneration (AMD) patients: Results from a multi-country cross-sectional study Euretina Congress. Lisbon, May 18-21, 2006.

C. Vitae Jordi Monés 62

10.2.177. D. Pauleikhoff, J. Lotery, J. Mones, G. Soubrane, A. Cruess, G. Zlateva, GERMANY. Impact of neovascular age-related macular degeneration on medical status, daily living and health resource utilisation: A survey of five countries Euretina Congress. Lisbon May 18-21, 2006.

10.2.178. Chair Session Free Papers New Therapies on AMD. Euretina Congress. Lisbon May 18-21, 2006.

10.2.179. J. Mones, Two-year efficacy results from MARINA, a randomized, controlled, Phase III study of ranibizumab for minimally classic or occult choroidal neovascularization secondary to AMD Euretina Congress. Lisbon May 18-21, 2006.

10.2.180. Curso de Avances e Innovaciones en Oftalmología. Ranibizumab y Bevacizumab en el tratamiento de la DMAE exudativa. Barcelona, June 1-2, 2006.

10.2.181. Tratamiento de la DMAE exudativa mediante Bevacizumab. Resultados a 6 meses. Comunicación libre. Congreso de la Sociedad Española de Oftalmología A Coruña, Septiembre 27-30, 2006.

10.2.182. Resultados del Ensayo Marina a 2 años de Ranibizumab (Lucentis®) intravítreo para el tratamiento de las lesiones ocultas y mínimamente clásicas secundarias a DMAE exudativa. Congreso de la Sociedad Española de Oftalmología A Coruña, September 27-30, 2006.

10.2.183. Resultados del Ensayo Anchor a un año comparando la eficacia del tratamiento de la DMAE exudativa con Ranibizumab (Lucentis®) y

C. Vitae Jordi Monés 63

de la Terapia Fotodinámica. Comunicación de Investigación. Congreso de la Sociedad Española de Oftalmología A Coruña, September 27- 302006

10.2.184. Hallazgos de Marina y Anchor: Tratamiento de membranas ocultas y clásicas subfoveales Dr. Jordi Mones Carilla. Symposium ANTIANGIOGÉNICOS: LLEGA LA NUEVA ERA 82 Congreso de la Sociedad Española de Oftalmología A Coruña, September 27-30, 2006

10.2.185. Directores Curso: Francisco Gómez-Ulla, Jordi Mones. TERAPIA ANTIANGIOGÉNICA EN PATOLOGÍA DE LA RETINA Colaboradores: José M. Ruiz Moreno, Luis Arias, Máximo Abraldes, Maribel Fernández, Joaquín Marticorena. Congreso de la Sociedad Española de Oftalmología A Coruña, September 27-30,2006

10.2.186. Bevacizumab en DMAE exudativa. Curso AVANCES EN EL TRATAMIENTO MEDICO QUIRURGICO DE LA PATALOGIA MACULAR. Congreso de la Sociedad Española de Oftalmología A Coruña, September 27-30, 2006

10.2.187. Quantification of improvements in visual acuity following treatment with intravitreal ranibizumab in patients with CNV secondary to AMD in the Anchor and Marina Trials. Retina Society – Club Jules Gonin Meeting. Cape Town, South Africa. October 16-20, 2006.

10.2.188. Tratamiento de la DMAE exudativa mediante Bevacizumab. Resultados a 6 meses. Curso DMAE; Hospital Germans Trias i Pujol. Catalunya, November 3, 2006.

10.2.189. Management of AMD. Breakfast for Experts. American Academy of Ophthalmology and Macula Society. American Academy of Ophthalmology Meeting. Las Vegas, November 13, 2006.

C. Vitae Jordi Monés 64

10.2.190. Vision improvement as the new “gold standard” of care in AMD. Looking forward in AMD > A new era in AMD treatment. Rome, March, 2007.

10.2.191. Advisory Board Allergan. Rome, March, 2007.

10.2.192. ¿Es avastin el hermano pobre de lucentis? I Simposium sobre Controversias en Oftalmología. Hospital de Bellvitge. Barcelona, March, 2007.

10.2.193. Update lucentis. New Therapies for AMD. 7th Euretina Congress. Montecarlo, May, 2007.

10.2.194. Against PDT still has a major role in the treatment of ARMD. Amsterdam Retinal Debate. 7th Euretina Congress. Montecarlo, May, 2007.

10.2.195. Quantification of VA improvements Over Two Years in the MARINA and ANCHOR Studies of Intravitreal Ranibizumab. Free papers. 7th Euretina Congress. Montecarlo May 2007

10.2.196. Antiangiogénicos. II Curso de Actualización de Retina y Vitreo. Oviedo, May, 2007.

10.2.197. La mejoría de la visión debe ser el nuevo estándar terapéutico en la DMAE. Curso Actualización DMAE. Sitges, May, 2007.

10.2.198. Quantification of VA improvements Over Two Years in the MARINA and ANCHOR Studies of Intravitreal Ranibizumab 0,3mg 0,5 mg for CNV secondary to AMD. Free papers. The Macula Society.

C. Vitae Jordi Monés 65

London June, 2007.

10.2.199. Mystery Case. Fluorescein cases for 2007.The Macula Society. London, June, 2007

10.2.200. Actualización en DMAE Directores: Jordi Monés i Carilla, Francisco Gómez-Ulla de Irazazábal Nivel: Avanzado. 83 Congreso de la Sociedad Española de Oftalmologia. Las Palmas de Gran Canaria, September 26-29 , 2007.

10.2.201. Simposium UNA NUEVA VISIÓN DE LA DMAE. Dr. Jordi Monés: Eficacia. 83 Congreso de la Sociedad Española de Oftalmologia, Las Palmas de Gran Canaria, September 26-29, 2007.

10.2.202. Ranibizumab for myopic choroidal neovascularization. The 7th International Symposium on Ocular Pharmacology & Therapeutics. February 28 -March 3, 2008.

10.2.203. Avastin for proliferative Diabetic Retinopathy. The 7th International Symposium on Ocular Pharmacology & Therapeutics. February 28- March 3, 2008.

10.2.204. Comunicación invitada: Aplicaciones Clínicas OCT Fourier Domain. XII Congreso de la Sociedad Española de Retina y Vítreo. Zaragoza, March 8, 2008.

10.2.205. Conferencia invitada: Aplicaciones Clínicas OCT Fourier Domain. Reunió International Meeting Topcon. Sevilla, March 14, 2008.

10.2.206. Efectos adversos anti VEGF BARRAQUER, Curso Instituto

C. Vitae Jordi Monés 66

Barraquer, Barcelona, April 2008

10.2.207. La Ceguera Evitable, DMAE y Retinopatia diabética.b Cuadernos Diálogos para la Salud, Centro Médico Teknon. April 18, 2008

10.2.208. Pro Neuroprotection. Implications of curretn treaments. Allergan advisory board. Annual Meeting Association for Reasearch in vision and ophthalmology. Fort Lauderdale, USA. May 1-5, 2008

10.2.209. Tractament actual de la degeneració macular associada a l’edat. Conferencia Escola Optica Girona. Girona, May 8, 2008

10.2.210. Tractament actual de la degeneració macular associada a l’edat. Col·legi d’òptics de Lleida. Lleida, May 22, 2008

10.2.211. Ranibizumab en neovascularización coroidea BARRAQUER Curs Barraquer. Barcelona, May 16, 2008

10.2.212. Avastin in Proliferative Diabetic Retinopathy. Primer Encuentro de Retina Quirúrgica. Menorca, June 13-14, 2008.

10.2.213. Tractament actual de la degeneració macular associada a l’edat. Conferència Col.legi d’Òptics, Tarragona, July 16, 2008

10.2.214. Ranibizumab en DMAE en regimen a demanda. 84 Congreso de la Sociedad Española de Oftalmología. Sevilla, September 26, 2008

10.2.215. Ranibizumab en MIOPIA. 84 Congreso de la Sociedad Española de Oftalmología. Sevilla, September 26, 200

C. Vitae Jordi Monés 67

10.2.216. DMAE i NVC. Clinica Juaneda. Palma de Mallorca, October 2008.

10.2.217. Ceguesa Evitable. Càtedra Unesco. Dia internacional de la visió. Escola d’Óptica de Terrassa. Terrassa, October 9, 2008.

10.2.218. Searching for the optimal dosing. Current update (AMD). 8th International AMD Congress. Firenze, October 17-18, 2008.

10.2.219. Safety and tolerability of two dosing regimens of ranibizumab in patients with subfoveal choroidal neovascularisation secondary to age- related macular degeneration: EXCITE secondary outcomes. XXVIth Meeting Club Jules Gonin. St. Moritz, Switzerland. September 11-14, 2008.

10.2.220. Member of Scientific Advisory Board. The 7th International Symposium on Ocular Pharmacology & Therapeutics. February 28- March3, 2008.

10.2.221. Jordi Monés Conferència magistral, The Friedman’s lecture: “ AMD: From desperation to Hope. Massachusetts Eye and Ear Infirmary, Harvard Medical School. Boston, Massachusetts, USA Febrer 18, 2009.

10.2.222. Jordi Monés: DMAE y RANIBIZUMAB Congreso bienal deEgresadoOftalmología centro medico nacional de occidente. Guadalajara, Mexico. March 5, 2009.

10.2.223. Jordi Monés: DMAE y TERAPIA ANTI PDGF Congreso bienal de EgresadoOftalmología centro medico nacional de occidente. Guadalajara, Mexico. March 5, 2009.

C. Vitae Jordi Monés 68

10.2.224. Jordi Monés: DMAE y TERAPIA MONOCLONAL ANTI UNION DE INTEGRINAS -‘FIBRONECTINA Congreso bienal de Egresado Oftalmología centro medico nacional de occidente. Guadalajara, Mexico. March 5 , 2009.

10.2.225. Jordi Monés, Lluis Arias Vitrectomía transconjuntival microincisional + rtPA + SF6 + Avastin. Congreso bienal de Egresado Oftalmología centro medico nacional de occidente. Guadalajara, Mexico. March 5, 2009.

10.2.226. Jordi Monés. ‘Current status of the examination and treatment of diabetic retinopathy’ L’Institute Cardiovasculare de Paris, Centro Médico Teknon. Barcelona, March 13, 2009.

10.2.227. Jordi Monés, Lluis Arias: Terapia anti PDGF combinada con anti VEGF en DMAE exudativa. Congreso Sociedad Española de Retina Vitreo. Madrid March, 2009.

10.2.228. Jordi Monés: Esport i Trauma Ocular. Acadeèmia de Ciències Mèdiques de Catalunya i Balears, Centre d’Alt Rendiment de Sant Cugat. Barcelona, March 27, 2009.

10.2.229. Jordi Monés, Samir Patel: Blocking Complement Factor 5 in neovascular AMD: Phase I Study. 9th Euretina Congress. Nice, France. May 14-17, 2009.

10.2.230. Jordi Monés: AMD Course, Dr Sobrane: Translating clinical evidence into treatment guidelines: In the search of the optimal dosing. 9th Euretina Congress, Nice, France 14-17 may, 2009.

C. Vitae Jordi Monés 69

10.2.231. Jordi Monés for the Ophthotech Anti-α5β1 Integrin in AMD Study Group Interference of Cell Survival Signals by Targeting α5β1 Integrin (with Volociximab) and Vascular Endothelial Growth Factor in Subjects with Neovascular Age-related Macular Degeneration (AMD) – Results of a Phase 1 Study. SOE 2009, The 17th Congress of the European Society of ophthalmology, 13-16 june 2009

10.2.232. Jordi Monés at the Reonet Novartis Advisory The 17th Congress of the European Society of ophthalmology, 13-16 june 2009

10.2.233. Jordi Monés at Eyesense Scientific Advisory Board. September 15th, Barcelona

10.2.234. Jordi Monés, Nueva evidencia de ranibizumab en DMAE neovascular: Estudios SUSTAIN y EXCITE.SEO Sociedad Española de Oftalmologia, 24-25 september 2009, Santander.

10.2.235. Jordi Monés, Lluis Arias, Marc Biarnés: Symposium Angelini. DMAE seca: El nuevo reto. Sociedad Española de Oftalmologia, 24-25 september 2009, Santander

10.2.236. Jordi Monés: Symposium OCT Spectralis: Avances en Técnicas diagnósticas para la DMAE seca. Sociedad Española de Oftalmologia, 24-25 september 2009, Santander.

10.2.237. Jordi Monés: Combined Inhibition of a5B1 Integrin and Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration – Phase 1 Study Retina Congress 2009 New York, september 29-0ct 4

10.2.238. Jordi Monés at the ERAB Allergan Advisory Board Meeting. Sept

C. Vitae Jordi Monés 70

29, New York

10.2.239. Jordi Monés: Potential Future Treatments for Neovascular AMD. 2009 International AMD and Retina Congress: Focusing of the issues of Today and looking to the future. 9-10 Oct, 2009.

10.2.240. Jordi Monés at Meet with the Experts: safety of anti VEGF treatments. 2009 International AMD and Retina Congress: Focusing of the issues of Today and looking to the future. 9-10 Oct, 2009.

10.2.241. Jordi Monés at Meet with the Experts: Daibetic Macular Edema and Retinal Vein Occlusion. 2009 International AMD and Retina Congress: Focusing of the issues of Today and looking to the future. 9- 10 Oct, 2009.

10.2.242. Jordi Monés at the Scientific Committee 2009 International AMD and Retina Congress: Focusing of the issues of Today and looking to the future. 9-10 Oct, 2009.

10.2.243. Jordi Monés “Phase III Study of Dexamethasone Drug Delivery System in the Treatment of Macular Edema Due to Branch and Central Retinal Vein Occlusion” Reunión Allergan, Madrid 16 octubre 2009

10.2.244. Jordi Monés at the ERAB Allergan Advisory Board Meeting, Irvine, California USA, Oct 22

10.2.245. Jordi Monés: Curso DMAE seca "El nuevo reto".40 Congrés de la Societat Catalana d’Oftalmologia Barcelona, 19-21 Nov 2009

10.2.246. Jordi Monés: Mesa Redonda Degeneración Macular Asociada a la Edad: Nuevas perspectivas terapeúticas. 40 Congrés de la Societat

C. Vitae Jordi Monés 71

Catalana d’Oftalmologia Barcelona, 19-21 Nov 2009

10.2.247. Jordi Monés: OCT alta resolución y autofluorescencia en DMAE seca. Curso Ultimas novedades para el tratamiento DMAE húmeda y DMAE seca. 40 Congrés de la Societat Catalana d’Oftalmologia Barcelona, 19-21 Nov 2009

10.2.248. Jordi Monés: DMAE Exudativa y atrófica. Nuevos advances. Ateneo de Madrid, Conferència Reunión –Colegio de Farmaceúticos. Madrid 24 nov 2009

10.2.249. Jordi Monés: DMAE: 20 anys de viatge. Curs optics. Escola òptica de Terrassa, 26 Nov 2009

10.2.250. Jordi Monés Anti-VEGF for Atypical Indications. The 8th International Symposium on Ocular Pharmacology and Therapeutics. Dec 3-6 2009, Rome Italy

10.2.251. Jordi Monés 'Anti-VEGF for myopic CNV. The 8th International Symposium on Ocular Pharmacology and Therapeutics. Dec 3-6 2009, Rome Italy

10.2.252. Jordi Monés Imaging autofluorescence and high resolution optical coherent tomography .symposium Heidelberg, The 8th International Symposium on Ocular Pharmacology and Therapeutics. Dec 3-6 2009, Rome Italy

10.2.253. Jordi Monés Anti-C5 therapy in DRY AMD (Ophthotech) The 8th International Symposium on Ocular Pharmacology and Therapeutics.

C. Vitae Jordi Monés 72

Dec 3-6 2009, Rome Italy

10.2.254. Jordi Monés, Nuevas perspectivas en el Tratamiento de la DMAE seca. IV Symposium sobre controversias en Oftalmologia. Hospital de Bellvitge, Barcelona Feb 2010.

10.2.255. Jordi Monés at the ERAB Allergan Advisory Board Meeting Paris, France january 14, 2010

10.2.256. Anti Complement C5 Therapy in DRY AMD: PHASE I CLINICAL TRIAL 33rd Annual Macula Society meeting in Tucson, Arizona, Feb 24-27, 2010

10.2.257. Terapia Anti Complemento C5 en DMAE SECA: ENSAYO FASE I. Congreso Sociedad Española de Retina Vitreo, Santiago de Compostela, march 5-6, 2010

10.2.258. DMAE seca: Nuevos avances. “Curso Formación Continuada Instituto Barraquer: Diagnóstico y tratamiento de las afecciones de la Mácula. Barcelona, April 16, 2010.

10.2.259. Jordi Monés Jordi Monés Investigator Meeting for the Phase 2 Anti-PDGF Study (OPH1001) World Ophthalmology Congress, Berlin June 4th 2010.

10.2.260. Jordi Monés at the Reonet Novartis Advisory. World Ophthalmology Congress, Berlin June 9th 2010

10.2.261. Avenços en el tractament de la DMAE exudativa i DMAE atròfica. Conferència al Col.legi de Metges de Lleida. Lleida, June 7, 2010

C. Vitae Jordi Monés 73

10.2.262. Nous tractaments en la DMAE. Conferència Col.legi d’Òptics de Barcelona. Barcelona, June 30, 2010

10.2.263. El tratamiento de las oclusiones venosas con un implante intravítreo de dexamentasona (OZURDEX) Ponencia Oficial Congreso de la Sociedad Española de Oftalmología, Madrid September 2010

10.2.264. Dry AMD: The new challenge. Heidelberg Spectralis Symposium. Congreso de la Sociedad Española de Oftalmología, Madrid September 2010

10.2.265. ¿Cuándo dejar de tratar con anti VEGF? Symposium Novartis. Congreso de la Sociedad Española de Oftalmología, Madrid September 2010

10.2.266. Course and Wet lab on ozurdex application, Uppsala, Sweden September 30, 2010

10.2.267. ERAB Advisory Board on Retinal Vein Occlusion, Chicago, October 17, 2010

10.2.268. The Rationale of the Fusion Regimen of intravitreal ranibizumab for exudative AMD. 10th International AMD and Retina Congress, Lugano, 29-30 October 2010 Switzerland.

10.2.269. Chairing Session on Management of Neovascular AMD - Current therapy and future options, 29 October. Speakers Frank Holz (Germany), Paolo Lanzetta (Italy), José Cunha-Vaz (Portugal) Peter Kaiser (USA) 10th International AMD and Retina Congress, Lugano, 29-30 October 2010 Switzerland.

C. Vitae Jordi Monés 74

10.2.270. Avenços en el Tractament de la DMAE. Escola Universitaria de Óptica y Optometría de Terrassa, November 26, 2010

10.2.271. 5th EVICR.net Members Meeting- London, 15/16 November 2010

10.2.272. Meeting of the AMD and Retinal Dystrophies Expert Committee of the European Vision Clinical Research Netwwork (EVICR.net) London, 15/16 November 2010

10.2.273. Reunión Comité Asesor para Eylea® (VEGF-Trap eye) Bayer Schering Pharma Barcelona, November 20, 2011

10.2.274. DMAE atrófica. Perspectivas presentes y futuras de tratamiento. Dr. Jordi Monés (Barcelona) Santa Lucia 2010. Sociedad Oftalmológica de la Comunidad Valenciana, Valencia, December 13, 2010

10.2.275. Region Europe Ophthalmics Network (REONET) advisory board meeting in Paris, France, on 13th January 2011

10.2.276. Meeting of the European writing Committee of the European guidelines for the treatment of the macular edema secondary to retinal vein occlusion. Paris, January 13, 2011

10.2.277. ERAB Advisory Board on Retinal Vein Occlusion, Paris January 15, 2011

10.2.278. Lecture "El nou pas en la DMAE exudativa" Col-legi Oficial d’Optics i Optometristes de Catalunya, Barcelona, january 24, 2011

C. Vitae Jordi Monés 75

10.2.279. Lecture "Esport i trauma ocular ". Col-legi Oficial d’Optics i Optometristes de Catalunya, Barcelona, january 24, 2011

10.2.280. 2011 Eylea Advisory Board Meeting on VEGF Trap, Bayer. Miami,February 13, 2011

10.2.281. Dispositivos intravitreos de liberación corticoides en edema macular diabètico", Symposium Vitreo Retina, Bausch and Lomb, Museo Reina Sofia, Madrid March 3, 2011

10.2.282. Member of the Local Advisory Board of The 2nd World Congress on Controversies in Ophthalmology (COPHy), Barcelona, Spain, March 3-6, 2011

10.2.283. Debate: Is SD-OCT necessary and sufficient to guide clinical decisions in neovascular AMD or diabetic macular edema? Yes U. Schmidt-Erfurth, Austria No J Mones Spain The 2nd World Congress on Controversies in Ophthalmology (COPHy) Barcelona, Spain, March 3-6, 2011

10.2.284. Debate: Is SD-OCT necessary and sufficient to guide clinical decisions in neovascular AMD or diabetic macular edema? Yes U. Schmidt-Erfurth, Austria No J Mones Spain The 2nd World Congress on Controversies in Ophthalmology (COPHy) Barcelona, Spain, March 3-6, 2011

10.2.285. Jordi Monés, Moderator of the Round Table Management of Retinal Vein Occlusion The 2nd World Congress on Controversies in Ophthalmology (COPHy) Barcelona, Spain, March 3-6, 2011

C. Vitae Jordi Monés 76

10.2.286. Ophthotech Advisory Board ARVO Meeting, Fort Lauderdale May 2, 2011

10.2.287. ERAB Advisory Board on Retinal Vein Occlusion, ARVO Meeting, Fort Lauderdale May 3, 2011

10.2.288. Iluvean Allimera Advisory Board Euretina Meeting. London UK May 25 2011

10.2.289. 2nd 2011 Eylea Advisory Board Meeting on VEGF Trap, Bayer. Euretina Meeting. London UK, May 27, 2011

10.2.290. Novartis Advisory Board Euretina Meeting. London UK, May 28, 2011

10.2.291. ERAB Advisory Board on Retinal Vein Occlusion, Euretina Meeting. London UK, May 29, 2011

10.2.292. Análisis de los resultados del Estudios CATT e IVAN Día de la Subespecialidad. Congreso de la Sociedad Española de Oftalmología, Oviedo SPAIN, 21 Sept, 2011

10.2.293. Hyporreflective wedge in geographic atrophy secondary to AMD. Un under-reported finding. Reunión Expertos y Junta de la Sociedad Española de Retina Vitreo. Congreso de la Sociedad Española de Oftalmología, Oviedo, SPAIN 21 Sept, 2011

10.2.294. Nuevos hallazgos mediante OCT spectral domain en DMAE atrófica. Symposium Bloss, Congreso de la Sociedad Española de Oftalmología, Oviedo, SPAIN 22 Sept, 2011

C. Vitae Jordi Monés 77

10.2.295. Eficacia y seguridad. Resultados del estudio CATT. Congreso de la Sociedad Española de Oftalmología, Oviedo, SPAIN 22 Sept, 2011

10.2.296. Algoritmos de tratamiento de las oclusiones venosas de retina. Simposium Allergan. Congreso de la Sociedad Española de Oftalmología, Oviedo, SPAIN 22 Sept, 2011

10.2.297. Camp Nou Sense Fum. Assemblea de Socis Compromisaris del Futbol Club Barcelona, 24 sept, 2011.

10.2.298. Does foveal swelling exist in foveal sparing of geographic atrophy secondary to AMD?. Spectralis Meeting. Edimburg, UK 1 Oct 2011

10.2.299. The Rationale for the FUSION regimen in exudative AMD. Spectralis Meeting. Edimburg, UK 1 Oct 2011

10.2.300. The FUSION regimen. Novartis Advisory Board. American Academy of Ophthalmology. Orlando, 20 Oct, 2011.

10.2.301. Intravitreal safety delivery: Meet the experts 11 international AMD and Retina Congres, lisbon 4-5 nov 2011

10.2.302. Ocular neovacularization in RVO Meet the experts 11 international AMD and Retina Congres, lisbon 4-5 nov 2011

10.2.303. International Expert Summit. The Angiogenesis Foundation. Berlin, 14-15 nov 2011

10.2.304. Steering Committee meeting of Crystal and Bravo Trial for RVO.

C. Vitae Jordi Monés 78

Prague, 17 nov,2011

10.2.305. Prohibited Treatments during the Chrystal and Brighter Trials. Investigator Meeting, Prague, 17 nov,2011

10.2.306. Endpoints in Crystal and Brighter Trials. Investigator Meeting, Prague, 17 nov,2011

10.2.307. Utilidad de los anti VEGF en oclusión venosa de la retina. III Jornadas Vitreo Retina Canarias (VCR). Puerto de la Cruz, 26 Nov, 2011.

10.2.308. Targeting Anti Complement anti C5 therapy for geographic atrophy secondary to age-related macular degeneration. A phase I study. International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.309. Chair of Dry AMD and Free Paper Session. International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.310. ICG silent polypoidal vasculopathy with favourable response to thermal laser therapy. Wet AMD Panel. Case Presentation and Discussion. International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.311. Chair of Wet AMD II and Free Paper Session. International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.312. Targeting platelet Derived (PDGF) and vascular endothelial (VEGF) growth factors for neovascular AMD. Phase I and Phase II. International Symposium of Pharmacology and Therapeutics. Vienna,

C. Vitae Jordi Monés 79

Dec 1-4, 2011

10.2.313. Fusion Regimen for Ranibizumab; combination of OCT guided retreatment with fixed retreatment. (PRN+FIXED) for wet AMD. International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.314. ERAB Advisory Board Meeting on Retinal Vein Occlusion, International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.315. Jordi Monés, RVO expert panel meeting. Rome, 29th January 2012

10.2.316. Iluvean Allimera Advisory Board Meeting. WOC, Abu Dhabi, UAE February 17, 2012

10.2.317. Region Europe Ophthalmics Network (REONET) advisory board meeting. Valencia, Spain, March 1, 2012

10.2.318. Jordi Monés, Líneas de Investigación en la DMAE atrófica. Programa de Postgrado Diagnóstico y tratamiento de las afecciones de la mácula. Institut Univeristari Barraquer. Barcelona. March 16, 2012

10.2.319. Discussion: People with large drusen in both eyes are at increased risk of progressing to choroidal neovascularization or geographic atrophy or both following cataract surgery. Yes Y. Durlu, Turkey No J Mones, Spain . The 3rd World Congress on Controversies in Ophthalmology (COPHy) Istanbul, Turkey, March 22-25, 2012

10.2.320. Jordi Monés, Iluvien or Ozurdex. The 3rd World Congress

C. Vitae Jordi Monés 80

on Controversies in Ophthalmology (COPHy) Istanbul, Turkey, March 22-25, 2012

10.2.321. Jordi Monés, Moderator of the Round Table Management of Macular Edema from Retinal Vein Occlusions. The 3rd World Congress on Controversies in Ophthalmology (COPHy) Istanbul, Turkey, March 22-25, 2012

10.2.322. Jordi Monés, Inflammation and ME. Aria workshop. Enlighten meeting, Barcelona, Spain, April 14th 2012

10.2.323. Jordi Monés, Clinical signs and characteristics: how to recognize inflammation in clinical practice. Aria workshop. Enlighten meeting, Barcelona, Spain, April 14, 2012.

10.2.324. Jordi Monés, moderador, Seguridad sistémica de los fármacos de uso intravítreo. Actualización de las terapias intravítreas con fármacos Anti – VEGF Novartis. Barcelona, Spain, April 26, 2012

10.2.325. Jordi Monés, Moderator Poster Session 547. AMD Clinical Research VII Jordi M. Monés. Centro Medico Teknon, Institut de la Màcula i de la Retina, Barcelona, Spain. May 10, 2012 ARVO Meeting, Fort Lauderdale, Florida, USA

10.2.326. 6530/A532 - Hyporeflective Wedge-Shaped Band in Geographic Atrophy Secondary to Age-Related Macular Degeneration: An Under- reported Finding Jordi M. Mones, Marc Biarnes, Fabio M. Trindade. Centro Medico Teknon, Institut de la Màcula i de la Retina, Poster Session 547. AMD Clinical Research VII Barcelona, May 10, 2012

10.2.327. 6531/A533 - Optical Coherence Tomography Characterization of Apparent Foveal Swelling in Patients with Foveal Sparing Secondary to Geographic Atrophy. Fabio M. Trindade, Jordi Mones, Marc Biarnes.

C. Vitae Jordi Monés 81

Institut de la Màcula i de la Retina, Barcelona, Spain. Poster Session 547. AMD Clinical Research VII Barcelona, May 10, 2012

10.2.328. 6532/A534 - Reproducibility of Fundus Autofluorescence Patterns in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Marc Biarnes, Jordi Mones, Fabio M. Trindade. Institut de la Màcula i de la Retina, Barcelona, Spain. Poster Session 547. AMD Clinical Research VII. Barcelona, May 10, 2012

10.2.329. Jordi Monés, Evaluation of 2-year CATT and 1-year IVAN results. Novartis Canada Ophthalmology Advisory Board Meeting - Fort Lauderdale, FL. Canada, May 7, 2012.

10.2.330. Jordi Monés, Intravitreal Expert Group HFMEA Review Meeting Fort Lauderdale, Florida, USA. May 5, 2012

10.2.331. Jordi Monés, AMD experts group New trial discussion. Bayer Meeting, Fort Lauderdale, Florida, USA. May 8, 2012

10.2.332. Jordi Monés, Conferència “Barça sense fum: l’èxit d’una iniciativa pionera”, Jornada “Día mundial sin tabaco”, Centro Médico Teknon. Barcelona, May 31, 2012

10.2.333. Jordi Monés, Fusion regimen: ranibizumab in treatment naive patients with exudative age-related macular degeneration and high visual acuity. XXVIIIth Meeting of the Club Jules Gonin. Reykjavik, Iceland, June 20- 23, 2012

10.2.334. Campaign Presentation: "Quit Smoking with Barça" with the participation of John DALLI, Member of the EC in charge of Health and Consumer Policy; Sandro ROSELL, President of FC Barcelona and Jordi MONES i CARILLA, Medical Director of FC Barcelona. September 18, 2012.

10.2.335. Speaker training Eylea. Bayer. Dr. Jordi Monés, member of the Steering Committee. Berlin, September 24, 2012.

C. Vitae Jordi Monés 82

10.2.336. Vitreo-retina (Paneles 001 al 013). Dres. Ramón TORRES y Jordi MONÉS. 88 Congreso de la Sociedad Española de Oftalmología. Barcelona, September 27, 2012

10.2.337. Simposium: Controversias en retina. Panel de Discusión DMAE: ¿Es necesario el seguimiento mensual en DMAE? Extensión de los periodos de seguimiento. Dr. Jordi Monés . 88 Congreso de la Sociedad Española de Oftalmología. Barcelona, September 27, 2012.

10.2.338. Mesa: Terapia proactiva - cambiando el abordaje actual en el tratamiento de la DMAE. Tratamiento proactivo: Siguiente paso en el abordaje de la DMAE. Individualizar el tratamiento proactivo. Dr. Jordi Monés. 88 Congreso de la Sociedad Española de Oftalmología. Barcelona, September 28, 2012.

10.2.339. Presentación: Nuevo hallazgo en las capas de la retina de pacientes con atrofia geográfica secundaria. Dr. Jordi Monés. II Reunión de Expertos en Retina Heidelberg. Barcelona. September 27, 2012.

10.2.340. Round table discussion: Are EU citizens health literate and aware of healthy lifestyles? Dr. Jordi Monés. 15th European Health Forum Gastein. European Comission. Brusel•les. October 3-6, 2012.

10.2.341. Institutional opening speech: IV Jornadas de MuscleTech Network. Dr. Jordi Monés. Barcelona, October, 2012.

10.2.342. Conferencia: Degeneración macular asociada a la edad (DMAE). Dr. Jordi Monés. Associació Discapacitat Visual Catalunya. Barcelona. October, 2012.

10.2.343. Inaugurazione ufficiale LETTURA MAGISTRALE: In the search for the optimal regimen and new perspectives in the treatment of AMD. J. Monés. 3° Congresso Nazionale dell`Associazione Italiana Medici Oculisti. October 26, 2012.

C. Vitae Jordi Monés 83

10.2.344. Meet the expert session. Anti-VEGF therapy in other retinal diseases (excluding AMD, DR and RVO) The management of myopic CNV. Jordi Monés and Paolo Lanzetta. 12th International AMD and Retina Congress. Prague. November 2, 2012.

10.2.345. Session: The management of neovascular AMD. Interactive clinical case 4: Treatment of RAP in the anti-VEGF era. Dr. Jordi Monés. 12th International AMD and Retina Congress. Prague. November 3, 2012.

10.2.346. Conferencia inaugural: Barça sin humo y Quit Smoking with Barça: por unos corazones con futuro. V Congreso Clínico semFYC en Cardiovascular. Barcelona, November 22, 2012.

10.2.347. Taula rodona: Retina mèdica. DMAE seca. Dr. Jordi Monés. 43è Congrés de la Societat Catalana d’Oftalmologia. Barcelona, November 30, 2012.

10.2.348. Conferencia: Líneas de Investigación de la Barcelona Macula Foundation. Dr. Jordi Monés. A.A.R.P.C. Seu de l’ONCE. Barcelona. December 1, 2012.

10.2.349. Edema Macular Diabetic. Allergan Advisory Board Meeting. Barcelona. December 2, 2012.

10.2.350. Actualización en el manejo de la DMAE y el Edema macular. A cargo del Dr. Jordi Monés. Curso a cargo de la Delegación de Islas Baleares del Colegio Nacional de Ópticos –Optometristas de España (CNOO). Mallorca. December 15, 2012.

10.2.351. Ex-smokers are unstoppable. "Quit Smoking with Barça". A cargo del Dr. J. Monés. Delivering success stories in public health for EU citizens. EU Health Prize for Journalists 2012. European Comission. Brussels. January 30, 2013.

10.2.352. La experiencia de la campaña "Quit Smoking with Barça". Dr.

C. Vitae Jordi Monés 84

Jordi Monés.: IIIas Jornadas de la SCATT. CaixaForum, Barcelona. February 08, 2013.

10.2.353. Dry AMD. The Complement System in Dry AMD: a Therapeutic Target. Dr. Jordi Monés. International Symposium on Ocular Pharmacology and Therapeutics (10TH ISOPT Clinical). March 08, 2013.

10.2.354. Wet AMD. Combination Therapy Targeting VEGF and PDGF for Wet AMD by Jordi Mones. International Symposium on Ocular Pharmacology and Therapeutics (10TH ISOPT Clinical). Paris. March 09, 2013.

10.2.355. Wet AMD. Case Discussion/Wet AMD Panel. Panel: Paulo Lanzetta, Italy, Jordi Mones, Spain, Gisele Soubrane, France & Pravin Dugel, USA. International Symposium on Ocular Pharmacology and Therapeutics (10TH ISOPT Clinical). Paris. March 09, 2013.

10.2.356. Tobacco Control, Smoking Cessation and Sports Stadia. Establishing a Club-Led ‘Smokefree Stadia Policy’ for Camp Nou by Dr. Mones. European Healthy Stadia Conference 2013. Manchester City FC. March 21st, 2013.

10.2.357. Debate: Management of center-involved DME and 20/50 in pseudophake? Anti-VEGF by J. Mones. World Congress on Controversies in Ophthalmology (COPHy). Budapest. April 04-07, 2013.

10.2.358. Debate: Which regimen: PRN vs. Fixed regimen? Treat and extend by J. Mones. World Congress on Controversies in Ophthalmology (COPHy). Budapest. April 04-07, 2013.

10.2.359. AVANCES EN DMAE Coordinadores: Jordi Monés (España),

Lihteh Wu (Costa Rica), Virgil Alfaro (EEUU). Caracterización de hallazgos foveales y velocidad de progresión de la atrofia geográfica. Jordi Monés. XXI Curso Panamericano. Galicia. April 27, 2013.

C. Vitae Jordi Monés 85

10.2.360. Guest speaker. Novartis Canada Regional Consult Panel. Vancouver, British Columbia. May, 4th, 2013.

10.2.361. Novartis Scientific Experts Forum ‘Sharing experience in wet AMD: real choices for real patients?. “The optimization of anti-VEGF dosing regimens” Jordi Monés. 2013 ARVO Annual Meeting. Seattle, Washington. May 5th – 8th, 2013.

10.2.362. Assessment of linearity of growth in time in geographic atrophy secondary to age-related macular degeneration. 6298 Poster Board Number: D0114. Jordi M. Mones, Marc Biarnes. 2013 ARVO Annual Meeting. Seattle, Washington. May 5th – 8th, 2013.

10.2.363. Main Session: Dry AMD. Characterization of retinal layers in foveal sparing secondary to gepgraphic atrophy by Jordi Monés. 13th EURETINA Congress. Hamburg, Germany. September 26th-29th, 2013.

10.2.364. REONET Advisory Board. NOVARTIS. Amsterdam. October 4th, 2013.

10.2.365. Curso de actualización en investigación sobre enfermedades raras: distrofias de la retina. Distrofias de la retina: Diagnóstico, tratamiento y seguimiento de los pacientes. Dr. Jordi Mones. IIS-FJD Catedra Bidons Egara CIBERER y CIBER BBN. Universidad Miguel Hernandez. Madrid, España. Octubre 9, 2013.

10.2.366. EVICR.net Expert Committees. AMD and retinal distrophies. Coordinator: Jose Sahel, MD, PhD. Members: Rufino Silva, Bart Leroy, Adnan Tufail, Frank Holz, Jordi Monés, Ugo Introini. Co-opted Member: Carel Hoyng. The EVICR.net Annual Meeting. Paris, France. October 14-15th, 2013.

10.2.367. Institutional opening speeches Jordi Monés, FCB. 5th MuscleTech Network Workshop. Barcelona, Spain. October 14th-15th,

C. Vitae Jordi Monés 86

2013.

10.2.368. ROCHE SYMPOSIUM. Dr. Jordi Monés. 13th International AMD & Retina Congress. Londres, England. October 24th, 2013.

10.2.369. 13th International AMD and Retina Congress. The Long-Term Management of AMD: Efficacy, Safety and Economic Considerations. Keypad case presentations Sobha Sivaprasad, UK; Jean-Francois Korobelnik, France; Jordi Monés, Spain; Rafael Navarro, Spain. Panel Discusion. 25th October 2013. Dublin, Ireland.

10.2.370. ESASO Style Debates and ESASO Master Classes. Sessions concurrent: Delegates to attend one session from the choice below. Master Class 2: New imaging techniques: Instrumentation for visualizing the instruments of vision. Emin Ozmert, Turkey Jordi Monés, Spain. 13th International AMD and Retina Congress. Dublin, Ireland. October 25th, 2013.

10.2.371. Avenços en el tractament de la degeneració macular i altres malalties de la retina. Dr. Jordi Monés. Fundació Josep Palau Francas. Ripoll, España. Novembre 12, 2013.

10.2.372. Advisory Board Novartis. AAO Annual Meeting. New Orleans. November 16th- 19th, 2013.

10.2.373. Advisory Board Alcon. AAO Annual Meeting. New Orleans. November 16th- 19th, 2013.

10.2.374. Simposi Bayer. Dr. Jordi Monés. 44è Congrés de la Societat Catalana d'Oftalmologia (SCO). Barcelona, Espanya. Novembre 28-30, 2013.

10.2.375. Líneas de investigación en la DMAE atrófica. Dr. Jordi Monés. Diagnóstico y tratamiento delas afeccionesde la mácula. Programa de Postgrado. Institut Universitari Barraquer. Barcelona, Espanya. 14 de febrero de 2014

C. Vitae Jordi Monés 87

10.2.376. Subtle details in inclusion criteria may be the key for success of clinical trials for chronic conditions. Speaker: Dr. Jordi Monés. GLOBAL HEALTH VISION LECTURE SERIES. Sponsor: National Eye Institute (NEI). Co-sponsors: Fogarty International Center (FIC) AND NIH Global Health Interest Group (GHIG). National Institutes of Health (NIH) Main Campus, Bethesda, MD. February 19, 2014.

10.2.377. SESSION I. Dry AMD. Impact of a Lesion Size-Derived Classification of Geographic Atrophy in Progression Rate. Moderator and speaker: Jordi Monés. 37th Annual Scientific Program, Macula Society 2014. Key Largo, Florida. February 20, 2014.

10.2.378. Mesa Redonda: Manejo de la terapia intraocular. Criterios de importancia en el manejo terapéutico de la DMAE atrófica. Jordi Mones. XVIII Congreso De La Sociedad Española De Retina Y Vítreo. Sevilla, Spain. March 7-8, 2014.

10.2.379. Poster: Comparación entre luz azul, infrarrojo y multicolor en la identificación de las drusas reticulares. Dr. Hussein Almuhtaseb, Dr. Josep Badal MD, Marc Biarnés O.D., M.P.H. Dr. Jordi Monés MD, PhD. XVIII Congreso De La Sociedad Española De Retina Y Vítreo. Sevilla, Spain. March 7-8, 2014.

10.2.380. Vision Research Day. Novartis Ophthalmic and Alcon. Zürich, Switzerland. March 14-15, 2014

10.2.381. Retinnova. 7 años en la nueva era by Dr. Jordi Monés (Chairman Retinnova). Novartis. Madrid, Spain. March 28-29, 2014.

10.2.382. “II Guardons contra el càncer”'. Associació Espanyola Contra el Càncer (Aecc). Dr. Jordi Monés, Responsible of the Medical and Sport Performance Department of Futbol Club Barcelona, recull el Premi en representació del FCBarcelona. Barcelona, Spain. April 2, 2014.

10.2.383. Advisory Board de Bayer. Barcelona, Spain. April 24, 2014.

C. Vitae Jordi Monés 88

10.2.384. Advisory Board de Novartis. Madrid, Spain. May 25, 2014.

10.2.385. IV Curso de Actualización en Retina y Vítreo. DMAE no exudativa y Curso de casos clínicos. Dr. Jordi Monés. Instituto Oftalmológico Fernández-Vega de Oviedo, Spain. May 23-24, 2014.

10.2.386. Advisory Board de Roche. London, September 10, 2014.

10.2.387. Advisory Board de Teva. London, September 11, 2014.

10.2.388. Advisory Board de Eylea. London, September 11, 2014.

10.2.389. Advisory Board de Roche. Lampalizumab. London., September 11, 2014.

10.2.390. 14th Euretina Congress. “Ranibizumab: Expanding Horizons in RVO Management” & “What does early neovascular AMD look like?”. Dr. Jordi Monés, Chaiman and speaker. Novartis. London, September 11-14, 2014.

10.2.391. 14th Euretina Congress. “Performance characteristics of multicolour versus blue light and infrared imaging in the identification of reticular pseudodrusen” Dr. H. Almuhtaseb, Dr. J. Badal, Dr. M. Biarnés and Dr. Monés. London, September 11-14, 2014.

10.2.392. 14th Euretina Congress. Session: “Individually dosed ranibizumab, alone or combined with laser, versus laser alone in branch retinal vein occlusion patients with visual impairment due to macular edema- 6 month results of the BRIGHTER study”. Dr. Monés together with M. Larsen, F. Boscia, H. Gerding, I. Pearce, S. Priglinger, R. Tadayoni, M. Gekkieva and A. Lotery. London, September 11-14, 2014.

10.2.393. 14th Euretina Congress. Session “Efficacy and safety of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to central retinal vein occlusion- design and baseline characteristics of the CRYSTAL study”. Dr. Monés with P. Hykin, H.

C. Vitae Jordi Monés 89

Gerding, F. Boscia, R. Tadayoni,S. Priglinger, I. Pearce, W. Stubbings, M. Gekkieva and A. Cole. London, September 11-14, 2014.

10.2.394. Vitreoretinal Society (SERV) Symposium on pathological myopia: “Anti-VEGF therapy for choroidal neovascular membranes”. By Dr. Monés. London, September 11-14, 2014.

10.2.395. Conference Choroideremia: knowledge and therapy. “The classification and evolution of choroideremia and the structure of the retina in patients with the pathology” by Dr. Monés. Organised by Spanish Choroideremia Association with the collaboration of the University of the Basque Country. Vitoria, Spain. September 16-17, 2014

10.2.396. Jornada científico divulgativa. “Investigación en DMAE: exudativa y atrófica. Ensayos Clínicos y pre-Clínicos.” Ponente: Dr. Monés. Asociación de miopía magna con retinopatías (AMIRES). Hospital Clínico de Madrid, Spain. Octubre 13, 2014.

10.2.397. 6th MuscleTech Network Workshop. Institucional Opening Speech. Dr. Jordi Monés. Centro Tecnológico Leitat, el FCBarcelona y Aspetar. Fútbol Club Barcelona. Barcelona, Spain. Octubre 13, 2014

10.2.398. AAO Chicago Congress. Section VII: First-time Results of Clinical Trials, Part I. PM BRIGHTER and CRYSTAL Studies Jordi M Mones MD. Chicago. October 17, 2014

10.2.399. 14th ESASO Retina Academy. MasterClass 2: Chorioretinal dystrophies. Dr. Jordi Monés, Rafael Navarro. European School for Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey. November 14, 2014.

10.2.400. 14th ESASO Retina Academy. SESSION 4 Evidence-based management of retinal ischaemia Dr. Jordi Monés. European School

C. Vitae Jordi Monés 90

for Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey. November 14, 2014.

10.2.401. 14th ESASO Retina Academy. Retinamour Clinical Case Discussion (Medical) Chair: Lawrence Yannuzzi, USA. Panel: Christopher Brand, UK. Dr. Jordi Monés, Spain. European School for Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey. November 14, 2014.

10.2.402. 14th ESASO Retina Academy. SESSION 5 AMD Chairs: Ursula Schmidt-Erfurth, Austria Marco Zarbin, USA. AMD clinical trials update Jordi Monés, Spain. European School for Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey. November 15, 2014.

10.2.403. ENCUENTRO: “Patologías de la Retina”. Principales enfermedades de la retina: epidemiología en España y Cataluña. Futuro e Investigación en las Enfermedades de la Retina. DMAE: Definición, tipos, síntomas, factores de riesgo. Dr. Jordi Monés. El Periódico-Novartis. Barcelona, Spain. Noviembre 18, 2014.

10.2.404. Actualización en la Terapia para Distrofias Corio-retinianas. Dr. Jordi Monés. Fundación José Pastor Fuertes. Valencia, Spain. December 19, 2014.

10.2.405. Scientific Global Advisory Board Meeting. Alcon. New York. March 20-22, 2015.

10.2.406. RETINA I. Non–neovascular Age-related Macular Degeneration. Debate II: Minimizing worsening of geographic atrophy. Might be feasible with Lamplaziumb. Dr. Jordi Monés. The 6th World Congress on Controversies in Ophthalmology (COPHy). Sorrento, Italy. March 31- April 3, 2015.

10.2.407. RETINA II Neovascular Age-related Macular Degeneration. Debate I: First Line Therapy. Ranibizumab. Dr. Jordi Monés. The 6th World Congress on Controversies in Ophthalmology (COPHy).

C. Vitae Jordi Monés 91

Sorrento, Italy. March 31-April 3, 2015.

10.2.408. Retinal vein occlusions. Evaluation of ranibizumab for macular ischemia in retinal vein occlusion: evidence from the BRIGHTER and CRYSTAL studies. Dr. Jordi Mones. Annual Meeting Abstracts. ARVO 2015. Denver, Colorado. May 07, 2015.

10.2.409. Fovista Meeting. Barcelona. May, 15, 2015.

10.2.410. Investigator Meeting. Steering Committee at the International Multicenter Clinical Trials Proxima A and Proxima B on Geographic Atrophy (Roche). Barcelona. May 21, 2015.

10.2.411. Advisory Board Novartis. Paris, France. May 29, 2015.

10.2.412. OCT Angiography Meeting. Roma, Italy. June 6, 2015.

10.2.413. 1st CAM Study Meeting. Capri Meeting. Italy. June 7, 2015.

10.2.414. Global RVO Advisory Board Lucentis. Zurich, Switzerland. June 18, 2015.

10.2.415. Anti-VEGF differentiation: The next chapter in management of retinal diseases. Bayer Advisory Board. Nice, France. September 16, 2015.

10.2.416. AMD and More. “Nascent” Geographic Atrophy. Dr. Jordi Monés, Speaker and Moderator. 13th International SPECTRALIS® Symposium (ISS). Valencia, Spain. October 16, 2015.

10.2.417. GA phenotypes with cluster analysis. Dr. Jordi Monés. The Meeting of the European project Exploring the combined role of genetic and non-genetic factors for developing AMD: A systems level analysis of disease subgroups, risk factors, and pathways (EYE-RISK) Majorca, Spain. October 17, 2015.

10.2.418. Effect Of Macular Ischaemia On Visual Acuity Outcomes In Patients With Branch And Central Retinal Vein Occlusion Undergoing

C. Vitae Jordi Monés 92

Individualised Treatment With Ranibizumab 0.5 Mg: Results from the BRIGHTER And CRYSTAL Studies. Poster. Dr. Jordi Monés. Second prize. 15th ESASO Retina Academy. Barcelona, Catalonia. October 23, 2015.

10.2.419. Geographic atrophy in AMD. MasterClass Number 4. Camiel Boon and Dr. Monés. 15th ESASO Retina Academy. Barcelona, Catalonia. October 23, 2015.

10.2.420. Anti-VEGF vs PRP in Proliferative Diabetic Retinopathy. Session 4. Dr. Jordi Monés, member of the Panel Discussion. 15th ESASO Retina Academy. Barcelona, Catalonia.October 23, 2015.

10.2.421. PROXIMA EAC F2F Meeting. Steering Committee of the Roche Clinical Trials Proxima A and Proxima B to combat atrophic Age- Related Macular Degeneration (AMD). Dr. Jordi Monés, Member. Annual Meeting American Academy of Ophthalmology (AOO). Las Vegas. November 15, 2015.

10.2.422. Steering Committee on exudative AMD of the Vision Academy.. Annual Meeting American Academy of Ophthalmology (AOO). Las Vegas. November 14-17, 2015.

10.2.423. DMAE. Nuevas Perspectivas. Dr. Jordi Monés.3as Jornadas de la SEEBV. Madrid, Spain. November 20, 2015.

10.2.424. REONET Meeting. Zurich. December 3-4, 2015.

10.2.425. Progresos en la investigación de las enfermedades degenerativas de la retina. Dr. Jordi Monés. Asociación Mácula Retina.

Sevilla, Spain. December 10, 2015.

10.2.426. Cluster analysis for GA phenotypes. Jordi Monés/Marc Biarnés. Big data analysis and machine based learning. Rotterdam, The Netherlands. January 22, 2016.

C. Vitae Jordi Monés 93

10.2.427. Progression of GA. Complex Genetic Retinal Ophthalmology. J. Mones. 6th Euretina Winter meeting 2016. Rotterdam, The Netherlands. January 23, 2016.

10.2.428. Efficacy of ranibizumab treatment in retinal vein occlusion patients with retinal macular ischemia: 24-month data from BRIGHTER and CRYSTAL. Dr. Monés. ARVO. Seattle. May 5th, 2016.

10.2.429. Diagnóstico y tratamiento de las patologías maculares. Sesión DMAE. Dr. Monés. Curso Mácula 2016. Instituto Universitario Barraquer y Universidad Autónoma de Barcelona. Barcelona (Catalonia). June, 3th, 2016.

10.2.430. B-Debate: Fighting blindness. Future Challenges and opportunities for visual restoration. Dr. Monés, Scientific leader and member of the Scientific Committee. Organized by: BIOCAT and Obra Social “la Caixa” with Barcelona Macula Foundation: Research for Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona (Catalonia). September 6th and 7th, 2016.

10.2.431. Macular Degeneration. Where we are in clinical practice. Session 1. Molecular pathology and biomarkers in age-related macular degeneration (AMD). Dr. Monés, Scientific leader and member of the Scientific Committee. B-Debate: Fighting blindness. Future Challenges and opportunities for visual restoration. Organized by: BIOCAT and Obra Social “la Caixa” with Barcelona Macula Foundation: Research for Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona (Catalonia). September 6th and 7th, 2016.

10.2.432. Session 4. Photonics and imaging. Chair: Dr. Monés and Samir Patel. B-Debate: Fighting blindness. Future Challenges and opportunities for visual restoration. Organized by: BIOCAT and Obra Social “la Caixa” with Barcelona Macula Foundation: Research for Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona

C. Vitae Jordi Monés 94

(Catalonia). September 6th and 7th, 2016.

10.2.433. POSTER 2. Dark adaptation impairment in patients with drusenB- Míriam Garcia, Marc Biarnés, Anabel Rodriguez, Jordi Monés. Debate: Fighting blindness. Future Challenges and opportunities for visual restoration. Organized by: BIOCAT and Obra Social “la Caixa” with Barcelona Macula Foundation: Research for Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona (Catalonia). September 6th and 7th, 2016.

10.2.434. POSTER 3. Identification of phenotypes in geographic atrophy using cluster analysis. Marc Biarnés, Clara Ramon, Jordi Monés. B- Debate: Fighting blindness. Future Challenges and opportunities for visual restoration. Organized by: BIOCAT and Obra Social “la Caixa” with Barcelona Macula Foundation: Research for Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona (Catalonia). September 6th and 7th, 2016.

10.2.435. POSTER 4. Images of the microscopic in-vivo human retina acquired using AOSLO. David Merino, Marc Biarnés, Miriam Garcia, Jordi Monés, Pablo Loza-Alvarez. B-Debate: Fighting blindness. Future Challenges and opportunities for visual restoration. Organized by: BIOCAT and Obra Social “la Caixa” with Barcelona Macula Foundation: Research for Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona (Catalonia). September 6th and 7th, 2016.

10.2.436. POSTER 5. Innovative procurement for visually impaired people: Introducing the PRO4VIP project. Anna Borrell, Ramon Maspons, Jean Patrick Mathieu, Jordi Monés, Vincenzo Alberto Vella. B-Debate: Fighting blindness. Future Challenges and opportunities for visual restoration. Organized by: BIOCAT and Obra Social “la Caixa” with Barcelona Macula Foundation: Research for Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona (Catalonia). September 6th and 7th, 2016.

C. Vitae Jordi Monés 95

10.2.437. Therapeutic approaches to dry AMD. Main Session 10 - New Insights into Dry AMD. Dr. Mones. 16th EURETINA Congress - Copenhagen 2016. September, 11th, 2016.

10.2.438. Novartis Spain Advisory board. 16th EURETINA Congress - Copenhagen 2016. September, 9th, 2016.

10.2.439. Maculogix Advisory Board. 16th EURETINA Congress - Copenhagen 2016. September, 10th, 2016.

10.2.440. Novartis Advisory board. 16th EURETINA Congress - Copenhagen 2016. September, 11th, 2016.

10.2.441. Eye diagnosis Advisory board. 16th EURETINA Congress - Copenhagen 2016. September, 11th, 2016.

10.2.442. 8th Meeting of the Muscletech Network Workshop. Inaugural Session. Dr. Jordi Monés. Barcelona, Catalonia. October 3rd-4th, 2016.

10.2.443. FCB Universitas project, Sport Innovation Hub. Presented by Dr. Jordi Monés. October, 11th, 2016. FC Barcelona’s office. New York, USA.

10.2.444. Investigator Update Meeting Presentation of Lampalizumab (ROCHE). Dr. Jordi Monés. Congress of the American Academy of Ophthalmology (AAO). Chicago.October, 15th-18th, 2016

10.2.445. Alcon Retina Exchange Film Festival. Congress of the American Academy of Ophthalmology (AAO). Chicago.October, 15th-18th, 2016.

10.2.446. Biennial Ocular Regeneration Meeting. Boston. October, 15th- 18th, 2016.

10.2.447. Sports Technology Symposium 2016. 2nd Edition. Inauguration. Dr. Jordi Monés as Board Member of FCBarcelona and Comissioner of FCB Universitas.Barcelona, Catalonia. November 10th, 2016.

10.2.448. Clinical Session. Developments in research and new treatments for retinal dystrophies. Dr. Jordi Monés. Secció Retina. Hospital Sant

C. Vitae Jordi Monés 96

Joan de Déu (HSJD). Esplugues, Catalonia. November, 6th, 2016.

10.2.449. FCB Universitas project, Sport Innovation Hub. Presented by Dr. Jordi Monés. November 30, 2016. Bologna.

10.2.450. The prospects for research on dry AMD. Dr. Jordi Monés. Catalan Society of Ophthalmology (SCO). Barcelona, Catalonia. December 1st-3rd, 2016.

10.2.451. Fovista combination therapy for neovascular AMD. Retina Session. Dr. Jordi Monés. 13th International Symposium on Ocular Pharmacology & Therapeutics (ISOPT) Clinical. Rome, Italy. December 1st-3rd, 2016.

10.2.452. Emerging therapies for retinal degenerations. Dr. Jordi Monés. 13th International Symposium on Ocular Pharmacology & Therapeutics (ISOPT) Clinical. Rome, Italy. December 1st-3rd, 2016.

10.2.453. POSTER: Results of intravitreal aflibercept in patients with neovascular age-related macular degeneration without optimal response to anti-VEGF-A therapy. The Macbeth study (878-A0057). Marc Biarnés and Jordi Monés on behalf of the Macbeth Study Group. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Baltimore (USA). May 7-11, 2017

10.2.454. POSTER: The LITE study. (309-B0508) Validation of an adaptive optics scanning laser ophthalmoscope prototype in patients with degenerative retinal diseases. Lucia Lee Ferraro, MD; David Merino, PhD; Marc Biarnés, MPH, PhD; Miriam Garcia, OD, MSc; Anna Borrell, BSc; Pablo Loza, PhD; Jordi Monés,MD, PhD. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Baltimore (USA). May 7-11, 2017

10.2.455. Predictive testing for age-related macular degeneration: are we there yet? Dr. Jordi Monés. Special Interest Group (SIG). Annual

C. Vitae Jordi Monés 97

Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Baltimore (USA). May 7-11, 2017

10.2.456. DMAE atrófica. Etiopatogenia, Predecir y cuantificar el crecimiento de la atrofia geográfica. Clasificación de la autofluorescencia en la atrofia geográfica, para dummies y sus implicaciones. ¿Hemos entendido la enfermedad? ¿Todas las atrofias son iguales? Fenotipos y tasas de progresión. Análisis de clúster. “Nascent GA” y Hyper-reflextive dots. Nuevas hipótesis en los mecanismos fisiopatológicos de la atrofia. Dr. Jordi Monés. V Curso de Actualización en Retina y Vítreo. Instituto Oftalmológico Fernández- Vega. Oviedo, Spain. 19 May, 2017.

10.2.457. Baja visión 360º: por un buen control de la diabetes, por una mejor calidad de vida de las personas con baja visión. Dr. Jordi Monés. Associació de Diabètics de Catalunya, la Associació Discapacitat Visual Catalunya y Novartis. Barcelona, Catalonia. 26 May, 2017.

10.2.458. Deporte y trauma ocular. Dr. Jordi Monés. Col·legi Oficial d'Òptics Optometristes de Catalunya (COOOC). Barcelona, Catalonia. June 29, 2017.

10.2.459. Welcome & Drusen ooze: A novel hypotesis for age-related geographic atrophy. Dr. Jordi Monés. LIGHT 2017 -International Retinal Laser Society (LASER). Barcelona, Catalonia. September 7, 2017.

10.2.460. Free Paper Session 3 AMD I. Understanding the natural history of geographic atrophy secondary to age-related macular degeneration: Baseline data from proxima A. J. Monés. 17th EURETINA Congress. Barcelona, Catalonia. September 7, 2017

10.2.461. Eurotimes Satellite Education Programme. Symposia: Managing Retinal Diseases with Ranibizumab: New Evidence. Moderator: J. Monés, SPAIN. Sponsored by NOVARTIS. 17th EURETINA Congress. Barcelona, Catalonia. September 8, 2017

C. Vitae Jordi Monés 98

10.2.462. Euretina Update 7. Neovascular AMD – Novel Insights & Lessons Learned. Combination therapy with a platelet derived growth factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor in exudative AMD. 12.00 J. Monés. 17th EURETINA Congress. Barcelona, Catalonia. September 9, 2017

10.2.463. Eurotimes Satellite Education Programme. Symposia: Impact of Geographic Atrophy: Enhancing Our Understanding of the Disease Moderator: J. Monés, SPAIN. Sponsored by Roche. 17th EURETINA Congress. Barcelona, Catalonia. September 9, 2017

10.2.464. Geographic atrophy phenotypes using cluster analysis POS- 41688. M. Biarnés, J. Monés SPAIN. 17th EURETINA Congress. Barcelona, Catalonia. September 9, 2017

10.2.465. Drusen ooze: A novel hypothesis in geographic atrophy. ePOSTER- J. Monés, M. Garcia, M. Biarnes, A. Lakkaraju, L. Ferraro SPAIN. 17th EURETINA Congress. Barcelona, Catalonia. September 9, 2017

10.2.466. A swine model of selective geographic atrophy of outer retinal layers mimicking atrophic age-related macular degeneration. ePOSTER- 43339. J. Monés, M. Leiva, T. Pena, G. Martinez, M. Biarnes, A. Serrano, E. Fernandez SPAIN. 17th EURETINA Congress. Barcelona, Catalonia. September 9, 2017

10.2.467. Validation of an adaptive optics scanning laser ophthalmoscope prototype in degenerative disorders: The LITE study. ePOSTER-41696. M. Biarnés, D. Merino, L. Ferraro, M. Garcia, P. Loza, J. Monés, SPAIN. 17th EURETINA Congress. Barcelona, Catalonia. September 9, 2017

10.2.468. Nuevos retos y perspectivas en la investigación de la patología ocular. J.Monés. Bloque 1: Prevención e Investigación en Enfermedades que causan Baja Visión. Jornadas Tengo Baja Visión

C. Vitae Jordi Monés 99

“Ver para creer, compartir para avanzar, visibilizar para mejorar”. Begisare. Donosti, Euskadi. December 2, 2017

10.2.469. PreMeeting CAM. Bolzano, Italy. January 18, 2018

10.2.470. Drusen ooze: A novel hypothesis for GA. J. Mones. Session 1. New innovations in diagnostics. Imaging Meeting. EURAC Research. Bozen, Italy. February 2, 2018.

10.2.471. Lampalizumab program update. J. Mones. Session 2 Advances in therapies for retinal disease. Imaging Meeting. EURAC Research. Bozen, Italy. February 2, 2018

10.2.472. Interesting Clinical Cases featuring Multimodal Imaging. Panelists: B. Freund, J. Monés, A. Polito, F. Romanelli, D. Sarraf, A. Tufail, F. Viola. Imaging Meeting. EURAC Research. Bozen, Italy. February 2, 2018

10.2.473. Conferència inaugural. Evidència en àmbit geriàtric des d’altres especialitats. J. Monés. IV Update en Geriatria. Societat Ca-talana de Geriatria i Gerontologia (SCGiG). Barcelona, Catalonia. February 14, 2018

10.2.474. Natural History of Geographic Atrophy Secondary to Age- Related Macular Degeneration: Proxima A Data From the 1_Year Analysis of 100 Patients. Authors: N. Holekamp, J. Monés, G. Staurenghi et al. Macula Society. Beverly Hills, California. February 21- 24, 2018.

10.2.475. Dry AMD. Drusen Ooze: A novel hypothesis in geographic atrophy. J. Mones. Macula Society. Beverly Hills, California. February 21-24, 2018.

10.2.476. GA Phenotypes identification by cluster analysis. J. Monés. Dry AMD & Retinal Degeneration. Tel Aviv, Isarel. 14th ISOPT Clinical March 1-3, 2018

C. Vitae Jordi Monés 100

10.2.477. Consensus definition for atrophy assoiated with age-related macular degeneration on OCT (CAM Group). J. Monés. Dry AMD & Retinal Degeneration. Tel Aviv, Isarel. 14th ISOPT Clinical March 1-3, 2018

10.2.478. Debate I: Complement inhibition remains a promisions strategy for geographic atrophy. Retina V. Non-neovascular (“Dry”) Age-related Macular Degeneration. 9th Annual Congress on Controversies in Ophthalmology: Europe (COPHy EU). Athens, Greece. March 22-24, 2018.

10.2.479. 5545 — A0237 Natural history of geographic atrophy secondary to age-related macular degeneration: Proxima A data from the 1-year analysis of 100 patients. Giovanni Staurenghi, N. Holekamp, J. Mones, F. Tang, B. Tong, R. A. Cantrell, C. Brittain, J. Ehrlich, H. Lin, C. C. Wykoff. ARVO 2018. Honolulu, Hawaii. April 29 – May 3, 2018.

10.2.480. Retina / Retinal Cell Biology. 287 Dry AMD. Posters. Moderator: Jordi Mones. ARVO 2018. Honolulu, Hawaii. April 29 – May 3, 2018.

10.2.481. Optimal Management Strategies for Age Related Macular Degeneration. J. Mones. Invited symposium. American Society of Retina Specialists. 36th World Ophthalmology Congress (WOC2018). Barcelona, 16-19 June, 2018.

10.2.482. Future Approaches to Non-exudative AMD. J. Mones. Presentation. 36th World Ophthalmology Congress (WOC2018). Barcelona, 16-19 June, 2018.

10.2.483. Update on Macular and Vitreoretinal Surgery. J. Mones. Invited Symposium. . The Retina Society. 36th World Ophthalmology Congress (WOC2018). Barcelona, 16-19 June, 2018.

10.2.484. Impact of baseline characteristics on q12w status with brolucizumab in the Phase III HAWK and HARRIER trials. J. Mones.

C. Vitae Jordi Monés 101

Presentation. English Retina. 36th World Ophthalmology Congress (WOC2018). Barcelona, 16-19 June, 2018.

10.2.485. Progression of Early to Advancedc AMD. J. Mones. Invited Symposium. European Society of Retina Speciliats. 36th World Ophthalmology Congress (WOC2018). Barcelona, 16-19 June, 2018.

THESIS

10.3. Increased fundus autofluorescence, a biomarker of lipofuscin content, as

a risk factor for the progression of geographic atrophy secondary to age-

related macular degeneration. Autor: Marc Biarnés. Jordi Monés,

Director y Miembro del Tribunal. Barcelona, España. July, 2014.

10.4. Caracterización fenotípica y terapia génica del ratón Prpf31 A216p.

Autora: Ana María Aramburu Del Boz. Jordi Monés, Miembro del

Tribunal. Sevilla, España. December, 2015.

10.5. Desarrollo de nuevas estrategias terapéuticas para el tratamiento de

enfermedades degenerativas de la retina basadas en vectores no virales

y en técnicas de reprogramación celular. Autora: Ariadna R. Díaz

Tahoces. Jordi Monés, Miembro del Tribunal. Elche, España. December,

2015.

10.6. Implant secundari en pacients afàquics sense suport capsular: lents

fixades a l'iris. Autora: Paula Verdaguer. Directors: José Luis Güell

Villanueva i Jordi Monés Carilla. Tutor: José García Arumí. Barcelona,

Catalonia. 28 de novembre de 2016.

11. COLLABORATION IN JOURNAL EDITION and REVIEWER

11.1. Opthalmology

C. Vitae Jordi Monés 102

11.2. Scientific Referee of “ARCHIVOS DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA”

11.3. Member Editoral Board Retina Today Journal

11.4. Reviewer of Journal of Ocular Pharmacology and Therapeutics.

12. SCIENTIFIC SOCIETIES MEMBERSHIP

12.1. MACULA SOCIETY (Elected in 2002)

12.2. RETINA SOCIETY (Elected Corresponding Member in 2001)

12.3. CLUB JULES GONIN (Elected 2014)

12.4. AMERICAN SOCIETY OF RETINA SPECIALISTS (Elected 2009)

12.5. AMERICAN ACADEMY OF OPHTHALMOLOGY

12.6. EURETINA SOCIETY

12.7. EUROPEAN VISION INSTITUTE

12.8. ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY

12.9. EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH

12.10. SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA

12.11. SOCIEDAD ESPAÑOLA DE RETINA VITREO

12.12. ACADÈMIA DE CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS

12.13. SOCIETAT CATALANA D'OFTALMOLOGIA

12.14. MASSACHUSETTS EYE AND EAR INFIRMARY ALUMNI

12.15. INSTITUT BARRAQUER

C. Vitae Jordi Monés 103

13. LANGUAGES

13.1. Catalan

13.2. Spanish

13.3. English